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Abstract
Despite significant developments, critical care mortality remains high at ~ 20-30%. 
Muscle wasting with protein breakdown is frequently seen in critically ill patients with 
increased amino acids release from muscle tissue, of which alanine and glutamine 
compose a large proportion. Plasma glutamine is rapidly utilized and circulating plasma 
glutamine declines rapidly. Low plasma glutamine concentrations correlate with 
mortality in critical illness and intravenous glutamine supplementation improves 
survival of the critically ill patient. The precise mechanism whereby this protection is 
afforded remains uncertain, although evidence suggests that glutamine plays an 
important role in the ability of cells to respond to stress.
The expression of stress or heat shock proteins (HSPs) is one of the most highly 
conserved mechanisms of cellular protection. Increased intracellular HSP content is 
associated with a striking preservation of muscle mass and function and low muscle 
and semm HSP 70 content in severe trauma correlate with increased mortality. 
Glutamine infusions facilitate increased HSP expression. Further, glutamine infusions 
enhance HSP content in multiple organs of the rat with a significant protection of these 
organs from damage during sepsis and a mortality advantage. This has resulted in the 
hypothesis that glutamine deficiency leads to a modified HSP content of muscle cells 
and a diminished ability to mount a stress response. Administration of glutamine will 
have a direct and beneficial effect on the HSP content of muscle in cell culture and 
during critical illness.
To test the hypothesis a muscle cell culture model was established and cells treated 
with a range of glutamine concentrations during differentiation (O.l-lOmM glutamine). 
The effect of modified glutamine concentmtion on the ability of cells to mount a stress 
response to hyperthermia and TNF-a stress (0.5-5mM glutamine) was determined. A 
pilot clinical trial (which was double blind randomized controlled) was also undertaken 
which comprised of treatment of patients with sepsis with one large intravenous 
glutamine dose (0.5g/kg bodyweight) early during critical illness. Muscle HSP content 
was measured at baseline and at 48 and 96 hours after initiation of treatment.
During myoblast cell differentiation, an extracellular glutamine deficiency correlated 
with increased HSP 70 content; high extracellular glutamine concentration resulted in 
little additional benefit. During stress (either hyperthermia or TNF-a treatment) 
extracellular glutamine deficiency correlated with a reduced intracellular HSP 70 
(highly inducible) content following stress compared with cells grown in normal 
extracellular glutamine concentrations. Glutamine intervention in human subjects 
demonstrated a significant correlation between plasma glutamine and muscle content of 
HSP 10, a B crystallin and HSC 70 (constitutively expressed).
Results emphasise the importance to correct a glutamine deficiency during stress and 
the need to maintain nonnal plasma glutamine concentrations during recovery, 
facilitating muscle regeneration and repair. A correlation was observed between plasma 
glutamine concentrations and muscle HSPs. However, one single dose of glutamine did 
not change the plasma glutamine concentration significantly and can therefore not be 
advocated.
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Chapter 1
Introduction
i
1.1. Critical illness - Magnitude of problem
1.1.1. Critical care medicine - Background
Critical care medicine has developed greatly in the last 50 years. This 
development was initiated by the polio epidemic in the early 1950s when 
there was insufficient respiratory support available for polio sufferers. This 
led to the use of life support techniques usually employed in operating 
theatres. Further, constant attendance of medical staff and establishing 
designated areas lead to a significant mortality reduction. Increasingly 
complex interventions have been made feasible by the ability to replace the 
role of a failing organ until recovery occurs. Critical care has developed 
greatly, for example more sophisticated ventilation techniques, cardiovascular 
support and renal support are now routinely employed. This development was 
necessitated by increasing demand and development in medicine and surgery. 
Different to other specialities, the decision to admit to critical care is based 
not on the nature of the disease suffered but by the support needed by the 
individual patient. This is illustrated by the definition of level of care 
published by the Department of Health. (DoH 2000) which stipulates the need 
of critical care i.e. admission to a High Dependency Unit (Level 2) by meeting 
the following criteria:
“Patients requiring more detailed observation or intervention including 
support for a single failing organ system or post-operative care and those 
‘stepping down’ from higher levels of care.”
The document further stipulates the need of critical care i.e. admission to an 
Intensive Care Unit (Level 3) by meeting the following criteria:
“Patients requiring advanced respiratory support alone or basic respiratory 
support together with support of at least two organ systems. This level 
includes all complex patients requiring support for multi-organ failure.”
This definition of critical care based on clinical features rather than different 
predisposing conditions create a rather heterogeneous critical care population 
(Carson and Shorr. 2003). The ultimate outcome will be influenced at least in 
part by the predisposing condition as well as the clinical syndrome the 
patients present with.
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The Systemic inflammatory response syndrome (SIRS) represents a non­
specific inflammatory response following a variety of severe clinical insults. 
The term 'systemic inflammatory response syndrome' (SIRS) was proposed by 
the consensus conference of experts in 1991 for the description of a non­
specific inflammatory process (Bone et al. 1992).
SIRS represents the physiological derangements in these conditions.
SIRS is defined by the presents of two or more of the following criteria:
(1) Temperature >38 or <36°C;
(2) Heart rate >90 beats per minute;
(3) Respiratory rate >20 breaths per minute or pCO <32 mm Hg;
(4) White blood cell count >12 x 109/1 or <4 x 109/1.
Following this definition it can be safely assumed that almost every patient 
admitted to critical care in the UK fulfils the definition of SIRS (Harrison et 
al. 2004). These insults can be as divergent as surgery, trauma, bums, 
infections, pancreatitis and other diseases (Claus et al 2010).
Regardless of its aetiology, any insult, if severe enough, induces the release of 
pro-inflammatory mediators and the formation of reactive oxygen 
intermediates, likely as a consequence of activation of polymorphonuclear 
leukocyte and other reticule-endothelial cells (Brown et al. 2006; Gutteridge 
and Mitchell. 1999; Marshall. 2005).
Many attempts have been made to quantify the degree of severity of illness for 
patients admitted to critical care. And indeed it has been shown that the 
severity of acute illness can be quantified by the degree of disturbance of a 
broad range of physiologic variables (Rowan et al.1994). Several scoring 
systems were developed to aid quantitative assessment of the severity of 
ilhiess, stratification of patient groups and evaluation of mortality within a 
critical care unit and between critical care units (Peter and Welte. 1997; Unertl 
and Kottler. 1997). Scoring systems were introduced due to the heterogeneity 
of critical care patients to objectively assess severity of illness. This enabled 
prognostication based on risk estimates derived from prognostic systems for 
the interpretation of crude mortality rates, potentially allowing inter-hospital 
and international comparison of clinical performance and quality of care 
(Carson S, 2003; Peter and Welte. 1997; Unertl and Kottler. 1997).
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The Acute Physiology and Chronic Health Evaluation II (APACHE II) score 
(Knaus et al. 1985) is one such score commonly used in UK critical care units 
(Harrison et al. 2004; Rowan et al. 1994).
The APACHE II score is validated for the use in the UK assessing the 
following 12 parameters (Knaus et al. 1985): temperature, mean arterial 
pressure, heart rate, respiratory rate, the alveolar-arterial gradient, arterial pH, 
serum sodium content, serum potassium content, serum creatinine content, 
haematocrit, white cell count, Glasgow coma scale. Points are added for age 
above 44 years on a graded scale. Points are further added for the presents of 
chronic disease states in combination with the mode of presentation, i.e. either 
elective postoperatively or non-elective (Figure 1.1). The score has been 
shown to not only provide a measure of illness severity, but also correlates 
with hospital mortality (Knaus et al. 1985).
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The APACHE II Severity of Disease Classification System
Physiological
variable
High abnormal Range Low abnormal Range
+4 +3 +2 +1 0 +1 +2 +3 +4
Temperature >41 39- 38.5- 36- 34- 32- 30- <29.9
(rectal in °C) 41.9 38.9 38.4 35.9 33.9 31.9
Mean arterial >160 130 110 70 - 50 - <49
pressure - - 109 69
(mmHg) 159 129
Respiratory >50 35- 25- 12- 10- 6-9 <5
rate (ventilated 49 34 24 11
or non-
ventilated)
Oxygenation: >500 350- 200- <200
A-aDOa 499 349
PaOi in >70 61- 55- <55
mmllG if nn £f\
FIO2<0.5 /u ou
Arterial pH >7.7 7.6- 7.5- 7.33- 7.25- 7.15- <7.15
7.69 7.59 7.49 7.32 7.24
Serum Sodium >180 160- 155- 150- 130- 120- 111- <110
(mEq/1) 179 159 154 149 129 119
Serum >7 6- 5.5- 3.5- 3- 2.5- <2.5
Potassium 6.9 5.9 5.4 3.4 2.9
(mEq/1)
Serum >3.5 2- 1.5- 0.6- <0.6
Creatinine 3.4 1.9 1.4
(mg/dl)
Double point for
acute renal failure
Haematocrit >60 50- 46- 30- 20- <20
(%) 59.9 49.9 45.9 29.9
wcc >40 20- 15- 3- 1-2.9 <1
(xl03cells/mm3) 39.9 19.9 14.9
Glasgow Coma
Score
15-actual score
Age (years) 45-54 = 2 points; 55-64 = 3 points; 65-74 = 5 points; >75 = 6
points
Chronic If the patients has a history of severe organ insufficiency or is
Health imnmno-compromised: 2 points for elective post-operative; 5
points for non-elective or emergency post-operative
Figure 1.1. APACHE II scoring sheet from Knaus et al. (1985).
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The systemic inflammatory response syndrome (SIRS) represents a 
multifaceted reaction involving inflammatory and anti-inflammatory 
processes, humoral and cellular reactions and circulatory abnormalities 
(Hotchkiss and Karl. 2003; Charalampos and Vincent. 2010). The diagnosis 
and evaluation of severity is made difficult by die non-specific nature of the 
signs and symptoms of SIRS. However, early diagnosis and stratification of 
severity is important to enable timely and specific treatment (Charalampos 
and Vincent. 2010). Biomarkers that reflect the severity and help with the 
diagnosis of SIRS could be of significant benefit. Other potential uses of 
biomarkers include prognostication of outcome and the response to therapy 
including recovery. C-reactive protein (CRP) is such a biomarker widely used 
in critical care which has been shown to reflect the inflammatory response 
(Povoa et al. 2005; Schmit and Vincent. 2008) which is not specific to 
infection alone but merely indicates the presents of an acute inflammatory 
process (Clyne and Olshaker. 1999). Importantly, the C-reactive protein is not 
part of the APACHE II score, the SOFA score and the SAPS score is however 
widely used as marker of inflammation in critical care (Charalampos and 
Vincent. 2010)
1.1.2. Number of admissions, length of stay, overall cost and
morbidity/ mortality
Current figures from the Intensive Care National Audit and Research Centre 
(ICNARC) estimate ~ 110 000 admissions per year to general adult intensive 
care units in England (2006). The estimated cost for Level 2 care per patient 
per day is £1345 and for Level 3 care the cost is £ 1716 per patient per day. 
The average care delivered in general adult ICUs has been estimated as 76% 
at level 3 care and 24% at Level 2 care. Average length of stay is 4.9 days, 
which gives an average cost of £7972 per patient per admission. Based on 
the above figures the annual cost for patients admitted to critical care is 
approximately £ 876 920 000 per year (Personal correspondence with 
ICNARC. 2006).
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Harrison et al (2004) published a case mix study of general adult critical care 
units from England, Wales and Northern Ireland. This study reported a 
median age of 63 years; 59% of these were male. The mean APACHE II score 
was 16.5. Critical care mortality was 20.3%; mortality at discharge from 
hospital was 30.8%.
1.1,3. Pathophysiology of critical illness - The role of oxidative
stress and the inflammatory response
During aerobic oxygenation O2 is reduced to H2O at the end of the 
mitochondrial respiratory chain. However during mitochondrial respiratory 
oxygenation single electrons leak causing partial reduction of 02 to the 
superoxide anion 02* (Frei. 1994). Superoxide is a radical with an unpaired 
electron and, as it lacks an electron, highly reactive. Superoxide is therefore 
called a reactive oxygen species (ROS). Superoxide occurs normally during 
aerobic oxygenation (Frei. 1994).
In health, there is a balance between the formation of ROS and their effective 
removal by protective antioxidants before they damage critical biological 
molecules. Under normal circumstances this balance is maintained between 
reactive oxygen species (potentially causing cell and tissue damage) and 
protective antioxidant mechanisms, removing these reactive oxygen species 
(Gutteridge and Mitchell. 1999).
Apart from appearing as products of aerobic oxygenation, ROS have several 
important functions in health and disease. Regulation of vascular tone, sensing 
of oxygen tension and regulation of functions that are controlled by oxygen 
concentration have been found to be physiological functions of ROS (Droge. 
2002). Further, ROS enhance signal transduction and modulates physiological 
responses in muscle cells after contractile activity. For example, the activity of 
antioxidant enzymes was increased by the modulation of the gene expression 
(Jackson. 2009).
ROS play an integral part in host defence. ROS has been linked to the 
activation of polymorphonuclear leukocyte and other reticulo-endothelial cells 
after exposure to infectious matter or after cell/ tissue injury (Brown et al.
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2006; Gutteridge and Mitchell. 1999; Marshall. 2005). For example ROS 
enhance signal transduction from the antigen receptor of lymphocytes (Droge. 
2002).
Neutrophils and monocytes as well as producing ROS during aerobic 
oxygenation, contain soluble oxidase enzymes with which molecular oxygen 
can be transformed into ROS (for example hydrogen peroxide and 
peroxynitrite). These ROS are released into phagosomes or into the 
extracellular environment and have the ability to damage biological 
macromolecules for example cellular membranes and lipoproteins, therefore 
“digesting” pathological microorganism by direct damage of ROS (Frei .1994; 
Marshall. 2005). The increased concentration of ROS is thought to augment 
the degradation of pathogens, might however by the same mechanism cause 
tissue damage to any other tissue in close proximity (Holman and Seba. 
1988).
Oxidative stress is represented by a mismatch of ROS and protective 
antioxidants and scavenger enzymes resulting in a lack of oxidative 
protection. It has been widely accepted that critical illness, among other 
factors, is associated with significant oxidative stress. This imbalance can 
results in tissue damage, exacerbate organ injury and thus overall clinical 
outcome by the unopposed activity of ROS (Crimi et al. 2006). Oxidative 
stress in turn has the propensity to worsen organ injury and therefore worsen 
overall clinical outcome by direct oxidative damage to cell membranes, 
lipoproteins and other macromolecules. Evidence suggests a correlation 
between illness severity and oxidative stress of critically ill patients, i.e. the 
greater the illness severity (expressed by APACHE score) the greater the 
oxidative stress (Alonso de Vega et al. 2000).
In critical illness the inflammatory response is a crucial mechanism of the host 
defence to guarantee integrity and survival of the host organism. This 
inflammatory response is normally tightly controlled to ensure initiation, 
maintenance and resolution of the inflammatory process to limit unwanted 
tissue damage (Figure 1.2; Texereau et al. 2007).
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The see - saw phenomenon of the Systemic Inflammatory Response syndrome
Figure 1.2 Schematic illustration of the Systemic Inflammatory 
Response Syndrome illustrating the intricate balance between pro 
and anti-inflammation adapted from Gutteridge and Mitchell, 
1999.
The activation of immune competent cells is generated by translocation of the 
transcription factor of NF fc B into the nucleus, as NF R B regulates the 
expression of genes important for the inflammatory response (Zingarelli. 
2005). Cytokines are important proteins to regulate this inflammatory process 
(Texereau et al. 2007). Activation of polymorphonuclear leukocyte and other 
reticule-endothelial cells causes early secretion of pro-inflammatory cytokine 
such as Tumour Necrosis Factor-a (TNF-a), Interleukin Ibeta (IL Ibeta) and 
Interleukin 6 (IL 6) which in turn stimulate various cell types and so 
coordinate the innate and acquired host defence response (Texereau et al. 
2007). NF R B can be further stimulated by cytokines such as TNF-a, which 
plays a central role in this process and provokes a broad range of immune and 
inflammatory reactions including fever, shock and tissue damage. TNF-a 
further generates nitric oxide (NO), ROS and cytokine release, since cytokines 
have the ability to further stimulate the production of additional cytokines.
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Following on from above, TNF-a has been suggested to activate and NF fc B 
in turn stimulates the secretion of TNF-a (Figure 1.3; Kaech and Calandra. 
2007).
Figure 1.3 Schematic illustration of NF k B activation. A variety of 
microbial products and inflammatory stimuli activate the inhibitor £ B 
protein kinase {IKK) complex, which phosphorylates Ik Ba associated 
with NF R B p50/p65 heterodimer. After degradation of Ik Ba, the NF £ B 
p50/p65 heterodimer is free to translocate into the nucleus to initiate 
transcription of genes of inflammatory and immune mediators adapted 
from Zingarelli, 2005.
The basic aim of the inflammatory response is to neutralise and eliminate the 
affecting agent and to repair the initial injury. Failure to achieve this will lead 
to chronic inflammation (Bellingan. 2007). An overwhelming inflammatory 
response can cause tissue damage, as outlined above (Holman and Seba. 
1988). It is therefore extremely important to tightly control such an 
inflammatory response. This becomes even more crucial when the initial 
insult has been resolved and resolution of inflammation needs to be rapidly
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achieved. This response is mediated by the secretion of anti-inflammatory 
cytokines such as Interleukin 10 (IL 10). A successful and adequate response 
to any given insult does therefore depend on an appropriate and balanced 
inflammatory response (Remick. 2007). This is evident by the fact that anti- 
TNF-a therapy did not produce a beneficial effect in severe critical illness 
(Abraham et al, 1998; Panacek et al, 2004). Similarly it is widely accepted 
that non-selective anti-inflammatory treatment with high dose steroid therapy 
canies no mortality advantage in severe sepsis (Keh and Sprung. 2004). 
Similarly a blunted TNF-a response conferred a mortality disadvantage 
(Heagy et al. 2003) possibly worsened by an elevated IL 10 response (Rigato 
and Salomao. 2003).
1.1.4 Critical illness and nutrition
The case-mix of patients admitted to critical care ranges from those admitted 
electively after major elective surgery to those admitted as emergencies after 
some surgical catastrophe for example burst abdominal aneurysm, 
gastrointestinal perforation, pancreatitis, major trauma, sepsis or respiratory 
failure (Harrison et al. 2004)
The variation in age range and previous health status may be extreme, and 
critical care units are now admitting increasingly more elderly, frail or 
malnourished patients whose nutritional reserve may be severely 
compromised (Griffiths and Bongers. 2005; Harrison et al. 2004). Critical care 
patients suffering from under nutrition with a limited nutritional reserve have 
a poorer outcome (Giner et al. 1996). Furthermore, having a low body mass 
index has been shown to be an independent predictor of excess mortality in 
multiple organ failure (Uehara et al, 1999). Critical care has developed 
significantly since the 1960s with the advent of more sophisticated techniques 
to support organ failure. Gastrointestinal failure requiring parenteral nutrition 
is a common problem of up to 10% of patients with critical illness (Reintam et 
al. 2006). Parenteral nutrition has been established as a treatment modality 
since the 1960s (Vinnars and Wilmore. 2003). Therefore nutritional support in 
general and specific nutritional compounds such as the amino acid glutamine
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has gained increasing interest in critical care medicine with the hope of 
preventing or attenuating the effects of malnutrition and nutrient depletion.
1.2. Interactions of glutamine, skeletal muscle and critical
illness
1.2.1. Glutamine
Glutamine is the most abundant free amino acid in the body. Glutamine a 
five-carbon amino acid containing two carboxyl groups one of which is bound 
to nitrogen, forming an amide group (Raymond D’Souza and Tuck. 2004; 
Young and Ajami. 2001; Figure 1.4).
O O
NH2
Figure 1.4 Schematic illustration of L-glutamine, (Koolman, 1994).
In the extracellular fluid, glutamine constitutes about 25% of the free amino- 
acid pool and in skeletal muscle glutamine constitutes more than 60% of the 
free amino-acid pool (Raymond D’Souza and Tuck. 2004; Young and Ajami. 
2001).
Glutamine has a wide range of functions (Koolman and Roehm. 1994; Biolo 
et al. 2005; Figure 1.5):
• substrate of protein synthesis
• controls acid-base balance via renal ammonia genesis.
• substrate for hepatic urea genesis
• substrate for gluconeogenesis
• fuel for enterocytes
• precursor for nucleic acid
• substrate for citrulline and arginine synthesis
• L-Arginine-NO-metabolism
• glutamine functions as ammonia scavenger
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• nitrogen donor
• nitrogen transport
• glutamate transport
• substrate for glutathione production.
Amino acids
Giutaminase - NH<
TCA cycle
Glutamine synthetase ♦ NH<
Pyruvate
Glucose
Nucleic acidProtein
synthesis
Glutathione
OrnithineArginine
Nitric oxide Urea
Figure 1.5 Illustration of glutamine metabolism and function. Adapted 
from Biolo et al. 2005 and Koolman and Roehm. 1994. GABA: gamma- 
amminobutyric acid, TCA cycle: Tricarboxylic acid cycle.
1.2.2 Skeletal muscle
Skeletal muscle has several main functions. It converts chemical energy into 
mechanical - and heat energy, which in turn can be used for movement, 
postural support and heat to maintain body temperature. Due to its specialised 
structure, muscle is able to contract, which facilitates movement and postural 
support (Silbemagel and Despopoulus. 1988).
Skeletal muscle contains bundles of individual muscle cells (= fibres) of 10 - 
100pm diameter and up to 20 cm length. Skeletal muscle fibres are 
surrounded by a plasma membrane called sarcolemma and contain multiple 
nuclei. The sarcolemma further encloses myofibrils. These myofibrils contain
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myosin and actin filaments. The arrangement of these contracting protein 
filaments is the cause of the striate appearance of skeletal muscle. On the one 
side the actin filaments are fastened to connective tissue, called the Z disk; on 
the other side, six actin filaments surround one myosin filament. The area 
where the myosin and actin filaments overlap appears darker and is called A 
band (Silbemagel and Despopoulus. 1988).
During a contraction the actin and myosin filaments glide along each other 
and therefore reduce the distance between the Z disks. The muscle contracts 
and shortens. This process is initiated by an action potential causing a rapid 
influx of Ca^ which binds to Troponin. The Ca^V Troponin binding frees the 
myosin/ actin binding site from tropomyosin, Actin and myosin bind under 
the influence of ATPase which reduces ATP attached to the myosin filament. 
This ATP loss causes a structural change to the myosin filament which results 
in muscle contraction. ATP is required to release the actin/ myosin binding 
(Silbernagel and Despopoulus. 1988).
1.2.3 Effects of critical illness on skeletal muscle
In mammalian cells proteins are constantly exchanged. The average rate of 
protein replacement varies greatly between tissues. The amount of 
intracellular protein replacement each day is sizeable. In a normal 70-kg adult, 
about 280 g of protein is synthesized and degraded each day; the majority of 
these proteins are intracellular proteins (Mitch and Goldberg. 1996; Figure 
1.6).
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Oral 
protein 
intake 
70g/ day
0.3g/kg/day
Plasma
protein
0.5kg
Total free amino-acid pool
~62g
Cell
proteins
5.8kg
4g/kg/day Amino-acid
Nitrogen
excretion
11.2g/day
Figure 1.6 Turnover of cellular and plasma proteins in a normal 70-kg 
man. (adapted from Mitch and Goldberg. 1996).
In catabolic states of sepsis or SIRS the overall breakdown of cell proteins 
increases to provide the essential amino acids required for protein synthesis 
and energy metabolism. Importantly during sepsis and SIRS there is a 
preferential loss of protein from skeletal muscle, but visceral organs lose little 
or no protein and the brain appears to be unaffected (Mitch and Goldberg. 
1996). The muscle wasting is further caused by disuse and a disease process 
called “critical illness polyneuromyopathy”. As suggested by the name, the 
underlying pathology can either cause an axonal poly neuropathy or a 
myopathy of some sort. It has been suggested that between 40 - 50% of 
critically ill patients suffer from critical illness polyneuro-myopathy. It has 
recently been suggested that critical illness myopathy and critical illness 
neuropathy coexist frequently (Schweickert and Hall. 2007; Khan et al. 2006) 
and are possibly different manifestations of the same pathology (Schweickert 
and Hall. 2007). The muscle wasting that occurs in catabolic states like sepsis 
or SIRS or following polyneuro-myopathy results largely from the accelerated 
breakdown of muscle protein, causing muscle wasting during critical illness.
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Amino acids are released from muscle tissue (Gamrin et al. 1996), of which 
alanine and glutamine compose 50% to 70% of the amino acid nitrogen 
released (Brooks et al. 1986). All of the above mentioned mechanisms - 
catabolic state, disuse, neuropathy and myopathy - cause significant changes 
to striate muscle during critical illness and indeed during critical illness mean 
fibre cross-sectional area is reduced by 3-4% per day (Helliwell et al, 1998). 
Further, protein content of muscle is reduced by 12% (Gamrin et al. 1997) 
overall body protein content is reduces by 15% compared with the normal.
1.2.4 The relationship between critical illness, glutamine and 
skeletal muscle
Glutamine is a non-essential amino acid and as such was not part of the 
available total parenteral nutrition regimes ‘in’ the 1960s, This was further 
influenced by the technical difficulties in the preparation and storage of 
glutamine containing solutions. L-glutamine has a very poor solubility, is not 
heat stable and therefore has to be stored at <4°C. Since glutamine is readily 
synthesised in most tissues and therefore classified as a dietary non-essential 
amino acid, it was considered appropriate to omit from total parenteral 
nutrition (TPN) regimes.
Although this is certainly true in the healthy human being, it has been 
suggested otherwise during situations of extreme stress, particularly stresses 
of prolonged duration. The mechanism for the reduction of muscle glutamine 
represents a demand for increased rates of glutamine utilisation at the whole- 
body-level and a relative impairment of de novo synthesis in skeletal muscle 
leading to a failure of systemic delivery to other organs and a conditional 
deficiency (Biolo et al. 2005). The lung and the brain also produce glutamine 
but skeletal muscle, by virtue of size and ability to synthesise glutamine de 
novo seems to be the most important source of glutamine for the blood stream 
(Figure 1.7).
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Muscle
- Proteolysis 15%
- De-novo synthesis 85%
Glutamine production 
80g/day
40g/day
Other tissues
• Lung
• Liver, 
adipose tissue
Dietary intake lOg/day
> 50% lost 
by first pass 
effect and 
metabolised 
in gut and 
liver
Figure 1.7 Schematic illustration of the source of glutamine illustrating 
muscle as the major glutamine source for intravascular glutamine. 
(Adapted from Biolo et al, 2005).
The initial response to septic stress is to export glutamine to the splanchnic 
bed and immune system from the free amino acid pool in muscle (Biolo et al. 
2005). This leads to protein breakdown and de novo synthesis of glutamine 
where de novo synthesis of glutamine may represent as much as 85% of the 
released glutamine (Kuhn et al. 1999). TNF-a (Chakrabarti. 1998) and 
endotoxin (Elgadi et al.1998) have been shown to increase glutamine 
synthetase mRNA in both lung and muscle, but in animals with loss of muscle 
mass due to starvation the increases in glutamine synthetase protein levels are 
seen predominantly in lung tissue signifying its greater importance when 
muscle mass is diminished.
Enteral dietary glutamine is extracted and utilised by the gut and liver (Haisch 
et al. 2000). Elsewhere in the body, on the arterial interface, glutamine rather 
than glutamate is the major transported substrate across cell membranes. This 
may be the key to the importance of the systemic plasma levels and
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(parenteral) delivery of glutamine for many tissues. Not only does the human 
body synthesise glutamine in many tissues it also holds it free in solution in 
skeletal muscle at a gradient of 32:1 muscle: plasma levels by active transport 
mechanisms (Biolo et al, 2005).
Vinnars et al (1975) were first to observe that following surgery, trauma or 
sepsis the free glutamine pool in muscle was reduced. Despite the rapid fall in 
the intramuscular concentration of free glutamine, transport out of muscle was 
maintained and clearance from the plasma by other tissues increased, 
indicating activated transport mechanisms in muscle (Mittendorfer et al,
1999) . Detailed stable isotope studies of glutamine metabolism in critically ill 
patients support the extensive and robust data of large animal studies that 
show net flux of glutamine from skeletal muscle to vital organs (Biolo et al. 
2005; Newshohne. 2001; Kuhn et al. 1999)
Jackson e/ al (1999) demonstrated that in newly admitted ICU patients, a 
similar production rate occurred but an increased metabolic clearance rate of 
glutamine from plasma also occurred, consistent with increased utilisation by 
other tissues and only modest correction of low plasma levels with 28 g/day of 
glutamine infusions. Later on during an intensive care stay, the efflux of 
glutamine cannot be maintained and plasma delivery declines (Biolo et al,
2000) . hi children with burns the plasma glutamine levels were reduced 
despite an increased metabolic turnover of glutamine and a near normal net 
efflux from the leg suggesting a relative inadequate production in critical 
illness (Gore and Jahoor. 2000). A decrease in muscle glutamine production 
was confirmed by Biolo et al (Biolo et al. 2000) in a study of 20 severely 
burned patients two weeks into their critical illness. The glutamine deficiency 
appears to be maintained even when moderate amounts of glutamine are 
supplemented parenterally (Palmer et al. 1996). A further study investigated 
the dose response of parenteral glutamine supplementation. Plasma glutamine 
concentration of patients responded by normalisation of plasma glutamine 
levels in a dose-dependent way, while free muscle glutamine concentration, as 
well as muscle protein synthesis and muscle protein content did not change 
significantly (Tjader et al. 2004). There is therefore strong evidence to 
contend that glutamine should be regarded as a ‘conditionally essential’ amino 
acid in critical illness. More importantly the question remains as to whether a
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low plasma and/or tissue glutamine concentration has an effect on morbidity 
or mortality. This question was addressed by an observational study from the 
Netherlands (Oudemans-van Straaten et al. 2001). In this study, plasma 
glutamine was measured in 80 critically ill patients. A low glutamine 
concentration was associated with higher mortality and a trend towards higher 
severity scores. The low plasma glutamine group was considerably older, 
possibly consistent with a reduced muscle bulk. The same findings were 
reproduced, i.e. low glutamine concentration was associated with higher 
mortality in a further study from Rodas et al (2012).
Work from other researchers (Wischmeyer. 2006b) has suggested that 
glutamine may work as a “pharmacological” agent as it conveys a morbidity 
and mortality advantage in a dose dependant pattern i.e. the higher the 
glutamine concentration given the greater the morbidity and mortality 
advantage (Wischmeyer. 2006b), To support this theory the researchers 
treated male Sprague-Drawley rats with varying doses of intravenous 
glutamine, followed by an endotoxin infusion to induce sepsis. A morbidity 
and mortality advantage the greater the glutamine dose administered was 
observed (Wischmeyer et al, 2001). Further, a mortality advantage was 
equally observed in several clinical studies (Griffiths et al. 1997; Powell-Tuck 
et al. 1999; Wischmeyer 2001). On the basis of the above studies a systematic 
review therefore suggested a beneficial glutamine effect on mortality the 
greater the dose administered (Novak et al. 2002) which was further supported 
by clinical practise guidelines (Heyland et al. 2009). However, this does not 
preclude these effects alongside that of correcting a deficiency. These two 
approaches - pharmacological effect or correcting a conditional deficiency - 
are obviously not mutually exclusive (Kent and Bongers. 2011).
1,2.5 Clinical outcome
The important question is whether exogenous glutamine provision affects 
outcome. However to understand the available data requires an appreciation of 
the timescales and consequences that could reasonably be expected. It is 
apparent when caring for patients on intensive care that some patients die
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early from the failure of a single organ that was involved in the primary 
pathology; and this usually involves just the brain, the heart or the lung. While 
patients die later from multiple organ failure which is “associated” with the 
development of secondary infections and is often a combined system failure 
(e.g. lung, liver and kidney) and is more a feature of non-recovery from initial 
or maintained insults. For instance although an acute inflammatory response is 
an early feature of most ICU presentations it is now appreciated that an 
optimised immune system, still capable of mounting normal inflammatory 
signalling, is a feature of survival. Perhaps the greatest challenge with any 
nutritional replacement therapy is to appreciate the likely time scales involved 
to show a clinically meaningful response. A benefit will likely be greatest in 
those who are most deficient for a prolonged period, sufficient to affect many 
systems e.g. the most severely ill with gut failure dependent solely on a 
glutamine deficient parenteral nutrition. Glutamine also needs to be given in 
sufficient dose and for sufficiently long periods. E.g. low dose continuous 
enteral delivery may all be consumed in first pass metabolism and not 
continuing glutamine after the initial treatment period in those not recovering 
within intensive care. Giving too little for too short a treatment period may 
well have little impact on survival, furthermore choosing an early endpoint 
e.g. 28 days may not disclose a real effect. Evidence suggests it is therapies 
that conserve or restore optimal circulation (Rivers et al. 2001) and 
metabolism (Van Den Berghe et al. 2001) that have shown real outcome 
benefit. Providing the optimal nutrition environment by preventing deficiency 
arising (Griffiths. 2001) is central to improved survival from Multi Organ 
Failure (MOF) (Griffiths. 2004)
1,2.6 Glutamine supplementation
1.2.6.1 Enteral supplementation
The evidence for enteral glutamine substitution, i.e. administration via the 
normal gastrointestinal route either by eating or a feeding tube, is currently 
not convincing. A large study from Western Australia randomised 363 
relatively well nourished critically ill patients to an enteral supplement of
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about 19g of glutamine per day (Hall et al 2003). Neither mortality 
(glutamine 15% (27/179) versus control 16% (30/184)) nor severe sepsis 
incidence (glutamine 21% (38/179) versus control 23% (43/184)) were 
affected. Typical of critical care, about 8% of patients required parenteral 
nutrition and did not receive the feed. The lack of any effect on mortality 
seems to be an observation consistent with previous lower dose enteral 
glutamine studies and may reflect the limited systemic availability of 
glutamine through the enteral route for it to be sufficient in the sicker patients 
to significantly influence survival (Haisch et al. 2000; Melis et al. 2005). This 
is probably not surprising as rapidly dividing cells (enterocyts) are using 
glutamine as energy source, so readily utilise enterally supplied glutamine. 
This would suggest that glutamine given enterally will not or to a lesser 
amount appear in the systemic circulation, which in turn may be the reason for 
the limited effect of glutamine on clinical outcome. This could be 
convincingly shown in a study comparing enteral with parenteral glutamine 
administration (Melis et al. 2005). hi this study, 20 g of alanine-glutamine 
dipeptide infusion was given to patients over 4 hours. Plasma glutamine 
concentration rose significantly with enteral and parenteral administration, but 
significantly more so when administration was parenteral. These findings 
would suggest the need for relatively higher glutamine doses when given 
enterally, to achieve the same systemic concentrations. Indeed researchers 
have shown that 14 day enteral supplementation in severe bums patients with 
0.5g/kg bodyweight of glutamine granules compared with placebo showed 
significantly increased plasma glutamine concentrations, improved wound 
healing and shortened hospital stay (Peng et al. 2004; Peng et al. 2006).
It has been postulated that the severity of illness correlates with the need for 
glutamine substitution (Novak et al. 2002, Heyland et al. 2009). This could be 
a further reason why enteral glutamine supplementation does not appear to 
carry a significant benefit compared to parenteral supplementation as severity 
of illness appears to correlate with gastrointestinal failure (Reintam et al. 
2006) i.e. patients with intact gastrointestinal function are less ill (Kent and 
Bongers 2011).
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1.2.6,2 Parenteral supplementation
Various trials have investigated the role of parenteral glutamine 
administration in critical illness, i.e. die intravenous administration of 
glutamine bypassing the gastrointestinal tract (Griffths et al. 1997, Powell- 
Tuck et al. 1999, Goeters et al. 2002, Dechelotte et al. 2006), One of the 
earliest trials examining glutamine administration in critical illness in a 
randomised controlled fashion was published by Griffiths et al (1997), These 
authors investigated a group of 84 severely ill critically care patients who 
were unable to receive enteral feeds and where major sepsis was the 
predominant feature. In a double blind manner, patients were randomised to 
glutamine containing total parenteral nutrition (TPN) or iso-caloric and iso- 
nitrogenous TPN without glutamine. On an intention to treat basis a 
significant reduced mortality benefit after 6 months in the glutamine group 
was observed, an outcome chosen to better reflect the known timescales of 
recovery of such patients. Survival in the glutamine group was 24/42 
compared with 14/42 in the control group (Griffths et al. 1997).
Using previously unpublished data, the same authors (Griffiths et al. 2002) 
showed that glutamine recipients have a significantly lower risk of dying from 
intensive care acquired infections. The difference in survival noted was almost 
all explained by reduced intensive care mortality from multiple organ failure 
in those patients remaining in ICU for a longer period and requiring at least 
five days of parenteral feed (p=0.05). In these veiy sick patients colonisation 
with Candida was high but fewer glutamine recipients acquired infections 
after a longer time on feeding and none died, whereas six control patients 
acquired Candida infections and died from multiple organ failure (p=0.02). 
This is a clinical illustration of how glutamine may restore the impaired T-cell 
mediated acquired immunity and allow optimal recovery of immune 
competent cells suffering from glutamine deficiency (Eliasen et al. 2006). 
There soon followed a further parenteral study (Powell-Tuck et al. 1999). hi 
this study 168 patients with the need for parenteral nutrition were randomised 
to either glutamine, supplemented TPN or control TPN of iso-caloric and iso- 
nitrogenous values. This study could not show a significant difference in 6 
month mortality or infectious complications. However there was a non-
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significant trend towards improved in-hospital mortality in medical and 
haematological patients in the glutamine-treated group. A major criticism of 
this study was a lack of patient homogeneity, even more so than usually 
observed in critical care studies (Carson and Shorr. 2003). Fewer very ill 
intensive care patients, represented by a lower mean APACHE II score, were 
recruited. However, it has been postulated that the very ill intensive care 
patients group are likely to be at the highest risk of glutamine deficiency 
(Griffiths et al. 2002) and will therefore benefit more from parenteral 
glutamine administration. Excluding very ill intensive care patients could 
therefore reduce any observed benefit.
Two further studies used the dipeptide alanyl-glutamine to overcome the 
solubility and stability issues of glutamine. 114 ICU patients in a French 
multi-centre randomised controlled trial (RCT), of predominantly complicated 
surgery or trauma patients showed on intention to treat analysis a significant 
reduction in complicated outcomes (41.4% v 60.7% p<0.05) that was 
predominately related to reduced infectious rate and pneumonias (Dechelotte 
et al. 2006). There was however no survival difference in the two groups. The 
median duration of feed was about 6-7 days; the maximum feed duration 
however was limited to only 10 days. This may be critical to any effect on 
outcome since it is possible that a longer period of treatment is required for an 
effect on survival to become apparent in those who were most deficient. The 
timescale effect was emphasised by a study involving 144 ICU patients in 
Germany (Goeters et al, 2002). In this randomised but un-blinded study the 
investigators decided a priori to analyse the data of 95 patients treated for 
more than five days and 68 patients treated for more than nine days. Plasma 
glutamines were low as expected and even by five days had not returned to 
normal since the feed only contained 0.2 g/kg body weight of glutamine 
compared with 0.35g/kg used in earlier studies. There was a small but non­
significant difference in clinical outcome in those patients fed for a shorter 
period but for those fed for more than nine days the survival measured at six 
months was significantly improved 22/33 v 13/35 (p<0.05).
A systematic review tried to address the important criticism of the paucity of 
trials and the small number of patients involved in these trials (Novak et al. 
2002). The authors examined randomised controlled trials of glutamine
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supplementation in surgical and critically ill patients using electronic 
databases and identified 14 trials. When aggregated, glutamine 
supplementation was associated with a risk ratio (RR) of 0.78 (95% 
confidence interval [Cl], 0.58-1.04) for mortality. Glutamine supplementation 
was further associated with a lower rate of infectious complications (0.81; 
95%, 0.64-1.00) and a shorter hospital stay (2.6 days; 95%, 4.5 to 0.7). The 
mortality benefit was even more striking in the trials that used the parenteral 
route (0,71; 95%, 0.51-0.99) and higher glutamine concentrations (0.73; 95%, 
0.53-1.00). The addition of trials published more recently has not altered the 
overall conclusion and when the 3 level 1 and 5 level 2 studies were 
aggregated, glutamine supplemented PN was associated with a significant 
reduction in mortality in critically ill patients (RR 0.67, Cl 0.48, 0.92, p = 
0.01) using a range of glutamine of 0.2-0.57 g/kg/day (Heyland et al. 2009). 
However, these findings have been questioned by three further trials that have 
been published in 2011. Grau et al (2011) demonstrated that glutamine 
supplemented TPN was associated with a reduced rate of infectious 
complications. These authors identified 127 patients with APACHE II score 
>12 requiring TPN for 5-9 days. TPN was supplemented with O.Sg/kg'Vday'1 
alanine glutamine dipeptide (Ala-Gin). This was associated with fewer 
urinary tract infections compared with the control group (2.3% versus 16.9% 
urinary catheter days, p=0.03) and fewer episodes of nosocomial pneumonia 
(8 versus 29 % days of mechanical ventilation, p=0.02). There was no 
statistical difference in intensive care mortality, hospital mortality and 6 
month mortality. The Scandinavian Glutamine Trial investigated 413 ICU 
patients with an APACHE II score > 10 at admission (Wemerman et al. 
2011). The patients were given enteral and/ or parenteral nutrition 
supplemented with iv glutamine for 12 hours per day. This was associated 
with a statistically significant increase in survival at 28 days in the group 
supplemented with iv glutamine, but no improved mortality at six months. 
The trial was stopped early due to recruitment problems and lack of funding, 
and was therefore unable to come to a definitive conclusion.
The largest published trial to date of glutamine supplemented TPN is the 
SIGNET trial which recently investigated 502 adults receiving HDU or ITU 
care at 10 centres in Scotland (Andrews et al. 2011). This study randomized
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patients to TPN containing glutamine, selenium or both in adult patients 
expected to require high dependency or intensive care for > 48 hours and 
required > 50% of their nutritional requirements to be met by parenteral 
nutrition. Patients randomised to glutamine received TPN supplemented with 
20.2g glutamine per day. Participants had a median APACHE II score of 20. 
59/126 (47%) of the patients received the glutamine supplemented trial TPN 
for < 5 days (median 5.1 days, max duration 7 days). This study could not 
show any significant benefit of parenteral glutamine supplementation with 
regards to infection rate or mortality. The negative results of this trial are 
however not surprising considering the small dose and short duration 
glutamine was administered.
1.2.7 Functional effects of glutamine
1.2.7.1 Effect of glutamine on glucose metabolism
It has been suggested, that glutamine, as parenteral infusion, can beneficially 
influence insulin mediated glucose utilisation, suggesting that sensitivity or 
responsiveness to insulin was enhanced (Borel et al. 1998) and in healthy 
adults can beneficially influence post-prandial insulin action, glucose disposal 
and fat oxidation (Iwashita et al. 2006). These findings reinforced the 
hypothesis that glutamine is beneficial during clinical situations associated 
with insulin resistance, which is frequently seen in critical illness. Two 
randomised controlled trials investigated this hypothesis further. In the large 
French RCT study discussed earlier (Dechelotte et al. 2006) in addition to 
demonstrating a substantial reduced infection and pneumonia rate in 
glutamine supplemented patients the investigators found a significant 
reduction of hyperglycaemias and a significant reduction in the number of 
patients requiring insulin. A further study examined insulin resistance in 
trauma. The investigators randomised 40 multiple trauma patients to receive 
either 0.4g glutamine per kg bodyweight per day or iso-caloric and iso- 
nitrogenous control (Bakalar et al. 2006). To assess insulin sensitivity eu- 
glycaemic clamp was performed on day 4 and day 8. The investigators 
showed that improved insulin sensitivity in multiple trauma patients was
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positively associated with parenteral glutamine supplementation. Grau et al 
showed improved glycaemic control in patients receiving TPN containing 
glutamine with a 54% reduction of the amount of insulin required for the same 
level of plasma glucose (Grau et al. 2011). In the light of these studies it is 
reasonable to accept that glutamine has a beneficial effect on insulin 
dependent glucose metabolism. This is clinically relevant when we look at the 
current evidence on glycaemic control in surgical and medical intensive care 
patients and its importance in view of morbidity and mortality (Van Den 
Berghe et al. 2001; Van Den Berghe et al 2006; Langouche et al. 2007).
1.2.7.2 Effect of glutamine on physiological and pathological 
mechanisms of infection
Critically ill patients are at increased risk of sepsis which is a major cause of 
mortality in critical care (Hotchkiss and Karl. 2003). Moreover a significant 
number of patients are admitted to critical care due to sepsis as primary 
diagnosis (Hotchkiss and Karl. 2003). It is therefore not surprising that sepsis 
and its avoidance is a major focus in current critical care research. It has been 
suggested for some time now that glutamine is a major fuel supply for 
immune cells. This appears to be the case for all immune competent cells. 
Moreover, optimal phagocytic and secretory activity of immune cells may be 
dependent on adequate glutamine supply (Andrews and Griffiths. 2002). 
Oehler et al (2002) investigated the effect of glutamine depletion on human 
leucocytes. These authors found that lymphocytes were less able to produce 
an adequate adaptive heat shock protein response to hyperthermia with a 
reduced glutamine concentration of 0.125mM, which is 25% of the 
physiological glutamine level, at the time of the stress response (Oehler et al. 
2002). The authors could further show an adaptation and recovery of 
monocytes with increased glutamine concentrations after a time of glutamine 
starvation, however no adaptation was observed at continuously low (33%) 
glutamine concentrations (Eliasen et al. 2006). A further study investigated 
the role of glutamine and peripheral blood polymorphonuclear cells (PMNC). 
The investigators showed that increased glutamine levels greater than 4mM
26
reduced the TNF a release from blood PMNCs after 4 and 24 hours of 
lipopolysaccharide (LPS) stimulation (Wischmeyer et al. 2003).
Recent evidence suggests that glutamine might play a role in NF fc B 
activation. Cells were exposed to LPS to provoke an inflammatory stimulus in 
a cell culture model containing varying concentrations of glutamine. The 
researchers found an inverse correlation between NF k B activation and 
glutamine concentration in media (Yu-Chen et al. 2012).
Enteral and parenteral glutamine supplementation is associated with reduced 
infectious morbidity in critically ill patients, as outlined in a recent review 
(Dhaliwal and Heyland. 2005). Various clinical studies have shown a benefit 
on infectious complications in patients with glutamine supplementation. 
However, others have not. Therefore glutamine administration either enterally 
or parenterally remains controversial.
1.2.7.3 Effect of glutamine on glutathione content of tissue
Reactive oxygen species (ROS) are thought to play a key role in the 
underlying pathophysiology of multisystem organ failure in critically ill 
patients. When oxygen availability is limited in the tissues of vital organs due 
to hypoperfusion, the cells shift from aerobic to anaerobic metabolism, 
thereby lowering the cellular energy charge. As a result, increased adenosine 
triphosphate (ATP) hydrolysis, a subsequent increase in adenosine 
monophosphate (AMP) levels and finally, an accumulation of purine 
metabolites, are found in ischemic tissues. Furthermore, during activation of 
the immune response, neutrophils, macrophages, and other competent immune 
cells may activate a plasma-membrane-associated NADPH oxidase system, 
capable of oxidising NADPH to NAD+, leading to further generation of 
superoxide radicals. Spontaneous dismutation of the superoxide radical 
generates hydrogen peroxide and molecular oxygen at physiologic pH. ROS 
not only lead to direct damage of cellular components, but also trigger the 
release of cytokines that further activate the inflammatory cascade (Heyland 
and Dhaliwal. 2006; Grimble. 1994). Glutathione in the reduced fonn is an 
important endogenous scavenger of ROS. Glutamine is an important substrate 
for glutathione. Therefore research has focused on the relationship between
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glutamine and glutathione and further, on the effect of low glutamine 
concentrations on glutathione concentrations in various cells during critical 
illness (Wernerman. 2003; Flaring et al. 2003). In critical care patients with 
septic complications following surgery, muscle free glutamine concentration 
was 72% lower in the sepsis group compared with a healthy control group 
(Hammarqvist et al. 1997). In parallel, during the first week in critical care, 
muscle reduced glutathione concentration and total glutathione concentrations 
were reduced to 57% and 62% of that of healthy controls respectively. 
Importantly, in this situation there is a significant correlation between muscle 
free glutamine and muscle total glutathione concentration (Wernerman et al. 
1999). In a further study reduced glutathione levels were shown to be reduced 
in blood in critical care patients (Flaring et al, 2005). The same research group 
showed that glutamine supplementation attenuated muscle glutathione 
depletion (Flaring et al. 2003).
1,3 Heat Shock Proteins - Background
Thus, there is considerable evidence that maintenance of plasma glutamine 
concentrations is beneficial. The mechanisms by which glutamine is 
beneficial are known to be:
• modification of the glucose metabolism
• manipulation of immune responses
• substrate for the antioxidant glutathione.
A newly emerging function of glutamine supplementation is via the activation 
of the adaptive and cytoprotective stress, or heat shock response although the 
mechanisms by which this might occur are poorly understood.
The expression of stress or heat shock proteins (HSPs) is one of the most 
highly conserved mechanisms of cellular protection and may be central to 
protect against the assault from systemic inflammation as seen during severe 
critical illness. Cells have been found to contain increased concentrations of 
HSPs after exposure to high but non damaging temperatures. This 
phenomenon was first discovered in 1962 by Ritossa (Ritossa. 1962) and in 
1975, Gemer and Schneider showed that the increase in HSP concentration
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carried a transient protection against subsequent stress (Gerner and Schneider, 
1975). Others have demonstrated that HSPs are increasingly produced after 
exposure to a wide range of cellular stresses (Kiang and Tsokos. 1998).
HSPs are categorised primarily according to their molecular weight. All HSPs 
are believed to act as chaperones, some have specific functions and are 
located in different compartments within the cell. By definition HSP 
production is increased after exposure to a wide range of environmental 
stresses and pathological states. Initially, Heat Shock Factor (HSF) becomes 
activated and enters the nucleus, binds to the Heat Shock Element (HSE) in 
the promoter regions of HSP genes. This leads to the activation of HSP gene 
expression and the synthesis of HSPs (Morimoto et al. 1992).
1.3.1. HSP 70
HSP 70s are the most commonly studied Heat Shock Proteins. Two forms of 
HSP 70 exist. The highly inducible HSP 70 which is significantly expressed 
during stress and the constitutively expressed but also inducible HSC 70 
(Hinault et al. 2006; Bromberg et al, 2007).
HSP 70 is present in the endoplasmic reticulum, mitochondria and cytoplasm 
and is implicated in a wide range of functions. As molecular chaperones, HSP 
70 moderates protein degradation, elimination and repair. HSP 70 supports the 
correct folding of proteins by an ATP dependant mechanism and is involved 
in ATP dependant unfolding. HSP 70s are also implicated in cell signalling 
pathways (Bromberg et al. 2007; Torok et al. 1997).
1.3.2 HSP 60
HSP 60 is located in the mitochondria where it is believed to be involved in 
protein folding. HSP 60 is believed to catalyse local unfolding of polypeptides 
in an energy dependant process. HSP 60 is further believed to prevent to 
proteins aggregation by passively binding of these aggregation-prone proteins 
to a state that is more readily foldable (Bukau and Horwich. 1998).
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1.3.3 The small HSPs
The small HSPs, HSP 27 and a B crystallin are found in the endoplasmic 
reticulum, mitochondria and cytoplasm are involved in prevention of cellular 
proteins from aggregation (Torok et al 1997). Heat shock protein 25 and a B- 
crystallin are structurally and functionally related small stress proteins 
induced by a variety of insults, including heat and ischemia. High 
concentrations of HSP 25 have been repotted in cardiac and skeletal muscle. 
The highest concentrations of a B-crystallin have been reported in eye lens 
fibre cells, cardiac muscle, striated muscle and lung. HSP 25 and a B- 
crystallin work as molecular chaperones and are believed to stabilise the 
cytoskeleton (Smoyer et al. 2000). HSP 10 is a small HSP, primarily located 
and functioning in the mitochondria. HSP 10 shares the same chromosome as 
its co-chaperonin HSP60 and has been associated with simultaneous up- 
regulation of both genes during instances of cellular stress.
In the mitochondria HSP 10 and HSP60 form the chaperonin complex. The 
chaperonin complex binds and stabilises newly synthesised proteins in the 
mitochondria and this complex is pivotal in maintaining mitochondrial 
homeostasis. Studies have indicated HSP 10 plays a significant role dining 
cellular stress. Up-regulation of HSP 10 is associated with improved outcome 
in ischaemia injury in cardiac tissue (Dillmann, 1999).
Research from our laboratory has identified a significant role for HSP 10 in 
protection against age-related loss of muscle mass and function, whereby 
overexpression of HSP 10 prevented the age-related loss of force generation 
(Kayani et al. 2010).
1.3.4. Intracellular HSPs, function in skeletal muscle
All HSPs act to preserve cellular integrity. An adequate HSP response is 
therefore critical for cell survival. Skeletal muscle normally adapts following 
stress, such that muscle is protected against subsequent damage (McArdle et 
al. 2001). This adaptation occurs following a variety of insults. Free radicals 
are generated, which in turn lead to a rapid adaptive response in the activity of
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protective enzymes, such as superoxide dismutase and catalase, and an 
increase in the cellular content of HSPs. An increase in these protective 
enzymes and HSPs protects die muscle tissue against subsequent exposure to 
damage (McArdle et al, 2004). Thus, when induced following cellular stress, 
HSPs appear to repair denatured proteins or promote their degradation 
following irreparable injury (Figure 1,8; Hightower. 1991).
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Figure 1.8 a) Function of HSPs in the unstressed cell, b) Protective effect 
of an increased content of HSPs in skeletal muscle. Adapted from 
McArdle et al, 2002.
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The protective effect of increased HSP content in muscle has been 
demonstrated in a cell culture model comparing heat treated C2C12 myotubes 
with none heat treated myotubes exposed to cell damaging agents. Cells 
treated with hyperthermia demonstrated increased HSP content and a 
significant cytoprotective effect against cell damaging agents (Maglara et al. 
2003). A similar protective effect in muscle was demonstrated in an animal 
model of HSP 70 transgenic mice whereby a transgenic increase in HSP 70 
content protected muscle from damaging exercise and improved recovery 
(McArdle et al, 2004). A further experiment investigated increased HSP 
content in an animal sepsis model. Animals were randomly assigned to one of 
four groups: heat treatment with sepsis, no heat treatment with sepsis, heat 
treatment and sham sepsis and no heat treatment with sham sepsis. Heat 
treatment resulted in a significant increase in HSP content and in turn a 
significant mortality benefit (Villar et al. 1994; Chu et al. 1997),
The protective effect of an increased cellular HSP content was very elegantly 
shown in a severe sepsis model of Sprague-Dawley rats. Sepsis was induced 
by a two puncture caecal ligation technique. At the time of operation an 
adenovirus expressing HSP 70 (AdHSP) was administered to the lung via an 
endotracheal tube. The sepsis-induced lung injury was markedly reduced as 
was mortality in these animals (Weiss et al. 2002). An inverse correlation was 
demonstrated between HSP 70 and the cytokines TNF-a, IL Ibeta and IL 6 in 
an animal lung injury model (Vreugdenhil et al. 2003).
1,3.5 Extracellular HSPs
A study in severe trauma patients found a correlation between patient survival 
and the ability to increase HSP 72 in serum, with a survival benefit in the 
group with a high HSP 72 content in serum (Pittet et al. 2002). Ziegler et al 
have shown a possible mortality advantage with an increased HSP 70 serum 
concentration after intravenous nutritional therapy containing an alanine - 
glutamine dipeptide (Ziegler et al. 2005). Both studies suggested that the 
serum HSP content might play a role in survival from critical illness. How this 
was reflected in tissue levels of HSPs and the mortality advantage was 
achieved is however not clear. Contrary to intracellular HSPs, extracellular
33
HSPs not only act as immunosuppressive molecules but also as potent 
immunostimulator molecules depending on the circumstances by which they 
interact with cells (Pockley et al. 2008). For example exposure of human 
monocytes to exogenous HSP 70 resulted in the up-regulation of pro- 
inflammatory cytokines such as TNF-a, IL Ibeta and IL 6 (Asea et al. 2000) 
and indeed there appears to be a correlation between HSP 70 concentration 
and severity of inflammation reflected by a correlation between HSP 70 and 
CRP, HSP 70 and TNF-a and HSP 70 and monocyte count (Njemini et al. 
2004). It is further accepted that HSP 70 can activate macrophages, dendritic 
cells (DC), natural killer (NK) cells, and hepatocytes (Pockley et al. 2008). 
Two sources of extracellular HSP have been postulated. HSPs can be released 
from healthy cells (Hightower and Guidon, 1989) and indeed an active 
mechanism has been reported (Hunter-Lavin et al. 2004). Others suggested 
that cell lyses is the main source of extracellular HSP (Basu et al. 2000).
1.3.6 HSP and glutamine
Glutamine appears to regulate protein turnover in cell cultures of myotubes, 
increasing the half- life of long-lived proteins. This may be related to a 
glutamine induced increase in HSP 70 (Zhou and Thompson. 1997). Further, 
glutamine appeals to be a potent enhancer of the stress response via HSP 
expression (Nissim et al, 1993) or increased HSP content in cells (Musch et al. 
1998; Wischmeyer et al. 1997). Thus, researchers have demonstrated 
increased HSP 70 content in tissue of the lung, liver and kidney in a porcine 
model after recurrent endotoxemia (Klosterhalfen et al. 1997) However, 
following sepsis, the HSP 70 content of lung tissue was impaired 
(Wischmeyer and Singleton. 2002), (Weiss et al. 2000) or only marginally 
increased (Singleton and Wischmeyer. 2006).
The observed attenuated stress response was reversed by glutamine infusion 
facilitating a significantly greater HSP content of lung tissue compared to 
placebo (Singleton et al. 2005a). The increased HSP concentration was 
associated with striking preservation of various organs including lung tissue 
(Wischmeyer et al. 1997; Wischmeyer et al. 2001). Others have shown that 
glutamine infusions, over a range of doses (0.15-0.75 g/kg), are able to
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enhance HSPs content of multiple organs of the rat (Wischmeyer et al. 2001). 
This induction occurs as early as 1 hour post-administration and persists for 
up to 72 hours post-administration. The authors further demonstrated that 
glutamine infusion prior to a septic insult was associated with protection 
against endotoxin-induced septic shock in the rat and could markedly decrease 
end-organ injmy and overall mortality. Further experiments illustrated that 
glutamine given post septic insult enhanced HSP 70 and 25 content, protected 
against acute lung injury and reduced end-organ injury and overall mortality 
(Singleton et al. 2005b). The survival benefit from glutamine was abrogated if 
a HSP inhibitor was administered (Singleton et al. 2005a).
It has been suggested that glutamine deficiency renders the cells incapable of 
an adequate HSP response (Oehler et al. 2002). Consequently it has been 
suggested (Wischmeyer 2006a; Wischmeyer 2006b) that glutamine 
administration influences the HSP response in humans and indeed the 
observed survival benefit of glutamine added to parenteral nutrition to meet a 
developing deficiency in the critically ill might reflect this. Moreover it has 
been demonstrated that glutamine substitution added to parenteral nutrition 
correlates with increased HSP 70 response in the critically ill (Ziegler et al. 
2005).
Half of severely ill intensive care patients are over 65 years with upwards of 
25% over 75 years of age. The ability of cells to induce HSPs following stress 
is reduced in aged humans and animals. Tissues from aged animals and blood 
cells from elderly humans both show a reduced production of stress proteins 
following thermal stress (Rao et al. 1999), It has recently been confirmed that 
an attenuated response occurs in skeletal muscle of aged rodents following a 
physiological stress. The HSP70 content of resting skeletal muscle was 
reduced in muscles from aged rodents and the production in response to a 
period of contractile activity was severely blunted in comparison with young 
animals (Vasilaki et al. 2002; Vasilaki et al. 2003). This lack of adaptation in 
HSP content in the aged animals may be related to a more general failure of 
adaptation to stress. Moreover, as mentioned above it has been observed that a 
low glutamine concentration might be associated with older age (Oudemans- 
van Straaten et al 2001). Further, HSP response in trauma might be blunted 
in older age (Pittet et al. 2002). Evidence to date is still lacking whether
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glutamine supplementation in this high risk group can improve plasma 
glutamine concentration, HSP responses and ultimately outcome.
1.4 Summary
Over the last 20 years, increasing evidence is emerging to support the use of 
glutamine supplementation ‘ ' cal illness. Animal work and clinical trials
have found a mortality and morbidity advantage of glutamine supplementation 
in critical illness. The advantage appears to be greater with increasing 
glutamine; further, the advantage is greater when given parenterally. Various 
modes of action have been postulated. Glutamine seems to have an effect on 
the immune system, the antioxidant status, glucose metabolism and heat shock 
protein response. It has been shown that increased intracellular and 
extracellular HSP concentrations convey a protective effect during damaging 
stress. This could be shown in cell culture models as well as animal models of 
sepsis and clinical studies of critical illness. Research has therefore 
concentrated in finding safe mechanisms to augment the HSP response 
particularly in skeletal muscle to improve clinical outcome.
1.5 Hypothesis
The overall hypothesis of the work is that:
1. Lower than adequate levels of extracellular glutamine will result in an 
altered ability of muscle cells to produce HSPs at rest and in response 
to physiological stress.
2. Higher than normal levels of extracellular glutamine will result in no 
additional ability of muscle cells to produce HSPs at rest and following 
a physiological stress compared with adequate levels of extracellular 
glutamine.
3. Further, that glutamine administration will have a direct effect on the 
HSP content of muscle of critically ill patients and the intracellular 
HSP content of muscle will correlate with the amount of glutamine 
given.
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CHAPTER 2
MATERIALS AND METHODS
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Model systems2,1.
2.1.1. Basic culture techniques of muscle cells
C2C12 cells were purchased derived from an existing mouse myoblast cell 
line (Yaffe and Saxel. 1977), C2C12 cells were cultured in 6-well plates at 
37°C in 5% CO2 in Dulbecco’s modified Eagle medium (DMEM, Sigma- 
Aldrich, Dorset, UK) containing 0.45% (w/v) glucose with 2mM glutamine, 
50 I.U,/ml penicillin, 50pg/ ml streptomycin and 12% foetal calf serum. Cells 
were cultured until 80% confluent; media was changed on alternate days 
throughout the experiment. When cells reached 80% confluence, media was 
changed to DMEM with 2mM glutamine, 50 I.U./ml penicillin, 50pg/ ml 
streptomycin (Invitrogen, UK) and 2% horse serum (Invitrogen, UK) to 
differentiate the cells into myotubes as previously described by Maglara et al 
(2003). Cells were harvested on day 9. Myotubes was assessed by light 
microscopy (Zeiss axiovert microscope, Carl Zeiss, Germany) at every media 
change (48hours). Representative light microscopy photographs were 
obtained on day 9 of differentiation, after which the myotubes were harvested 
in Dulbecco’s- phosphate buffered saline (D-PBS, Sigma-Aldrich, Dorset, 
UK).
The cells were centrifuged (Eppendorf centrifuge 5417R, Germany) at 
14,000g for 5mins. The cell pellets were re-suspended in 1% sodium dodecyl 
sulphate (SDS) containing a range of protease inhibitors (2.4.1) and sonicated 
on ice.
2.1.2. Clinical trial
2.1.2.1. Patient selection
2.1.2.1.1. Recruitment
All admissions to the Whiston hospital Intensive Care Unit and the Royal 
Liverpool University hospital Intensive Care Unit were screened for 
participation between June 2006 - June 2007. To be able to participate the
38
following inclusion criteria needed to be fulfilled. Further, all exclusion 
criteria needed to be absent.
2.1.2.1.2. Inclusion
• All admissions to intensive care less than 24 hours from admission 
with an
Acute Physiology and Chronic Health Evaluation II score (APACHE 
II) >10
• Proficient in reading and writing English to be able to understand the 
infonnation sheet and any other information given.
2.1.2.1.3. Exclusion
• Coagulopathy, defined as
1. International normalized ratio (INR) >1.7
2. Platelet count < 100 x 109/L
• Bleeding disorder
• Hepatic impairment defined as a total bilirubin concentration of more 
than 45 micromol/1 or a more than fivefold increase of Alanine 
aminotransferase (ALT) above normal
• <18 years of age
• Pregnancy
• Expected to be discharged within 48hours from admission as judged 
by the Consultant in charge at the day of screening for participation
• Expected to die within 48hours from admission as judged by the 
Consultant in charge at the day of screening for participation
• Malignant disease if not surgically resected.
• Unable to perform biopsy on clinical grounds
• On total parenteral nutrition
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2.1,2.1,4. Consent
The patients was entered into the study if they or their relatives on the patients 
behalf (should the patient be unable to give informed consent) agreed to take 
part. The study was explained, an information sheet was handed out and in the 
case of agreement the patient or relative was asked to sign a consent/assent 
form.
Retrospective consent was obtained as soon as possible in cases where 
relatives or next of kin signed an assent form.
2.1.2.2, Trial design
2.1.2.2.1. Randomisation
On recruitment the patients were block randomised for age (> 65 years) by the 
Whiston hospital pharmacy department to receive either glutamine (0.5g per 
kg bodyweight) or iso-caloric glucose.
2.1.2.2.2. Investigations
2.1.2.2.2,1. Muscle biopsy
Muscle biopsies were taken from the vastus lateralis of the thigh under local 
anesthesia (1% Lidocaine) using a Pro-Mag 2.2 biopsy gun (MD-TECH, 
Manan Medical Products, Northbrook, IL). Samples obtained (~50 mg) were 
immediately frozen in liquid nitrogen and stored at -80°C for later analysis. 
Once the biopsy was completed the womid was cleaned, closed with steri- 
strips and covered with an adhesive dressing (see Figure 2.1).
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Figure 2.1 Demonstration of muscle biopsy
A second and third biopsy were taken at 48 +/- 4hours post randomisation and 
at 96 +/- 4 hour post randomisation using alternate legs for each biopsy (same 
procedure as above). Coagulation status was checked before each biopsy. 
Biopsies was not performed when
• International normalised ratio (INR) >1.5
• Platelet count < 100 x 109/1
2.I.2.2.2.2. Blood samples
Blood samples were obtained before, at 48 and 96 hours after randomisation 
from an indwelling arterial catheter (standard device for patients on ITU) for 
plasma (Na EDTA tubes, S-Monovette, Nuembrecht, Germany) and serum (S- 
Monovette Serum Gel S, Nuembrecht, Germany ), centrifuged at 1500g for 
5min. Serum and plasma was stored at -80°C.
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2.1.2.2.3. Glutamine dosing
Glutamine (0.5g per kg bodyweight) was chosen in our study which resembles 
a large glutamine dose with no significant side effects in an alanine-glutamine 
dipeptide form (Tjaeder et al. 2004) The intravenous infusion was 
administered as early as possible from randomisation (~1 hour) over ~ 4 
hours.
2.I.2.2.4. Trial size
This clinical study was a pilot study. An exact power calculation was not 
possible as the primary endpoint was not tested in relationship to glutamine in 
humans before in the manner we proposed. Therefore the aim was to recruit 
30 participants, 15 in each group (Lancaster. 2004).
2.I.2.2.5. Flow chart describing patient study
30 patients (N = 30)
muscle biopsy at baseline (three passes/ right quadriceps)
<
 Glutamine treatment 
O.Smg/kg bodyweight 
N * 15
Given as infusion over 
4 hours
Iso-caloric 
glucose control 
N = 15
Given as infusion over 
4 hours
48 +/- 4 hours after randomisation 
2nd biopsy (three passes/ left quadriceps)
Coacvlato” statca w 11 be checked frtfQraeatft btomi fttowlM wllnotbe permed when 
•Ptetetot count < 100
96 +/- 4 hours after randomisation 
3rd biopsy (three passes/ right quadriceps)
IO0
Primary Outcome:
•Cheage inHSP concentration in serum end muscle 
•Che nge of flute mine concentration in serum
■ Proficient in reeding writing
Exclusion:
• Unebie to perform biopsy
Measurements: IMneu Severity scores: APACHE 11; SAPS at randomization. 2"a biopsy and 3"* biopsy
WCC, CRP, Temp daily as pert ol standard ITU care
Outcome Measurements Glutamine. HSPs and Cytokines from plasma/serum at time of baseline. I1-♦/ 3™ biopsy
Glutamine and HSP from muscle tissue, i.e. baseline *!■ 3n' biopsy
The patients will be followed up until they leave critical care. Mortality, length of stay on critical care, 
length of ventilation will be recorded.
Figure 2.2 Flow chart of clinical trial
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2.1.2.2.6. Other treatments
All patients received the same standard of care. Any treatment decision was 
decided by the consultant in charge and was completely independent of the 
clinical trial.
2.1.3. Outcomes
2.1.3.1, Primary outcomes:
• Change in HSP concentration in serum or muscle
• Change of Interleukins TNF-a, IL 1(3, IL 6 and IL 10
• Change of glutamine concentration in plasma
• Change of total and oxidised glutathione in plasma and muscle
2.1.3.2. Secondary outcomes:
• Change of Severity Scores (APACHE II, Simplified Acute 
Physiology Score (SAPS), Sequential Organ Failure 
Assessment Score (SOFA)
• Change in white cell count (WCC), C-reactive Protein (CRP), 
temperature
• Length of ventilation
• Length of critical care stay
• Critical care mortality
2.1.3.3. Measurements
Illness severity scores (APACHE II, SOFA and SAPS) were assessed at 
randomization, at 48hours and 96hours post randomisation. WCC, CRP, 
Temp were recorded daily as part of standard ITU care.
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2.I.3.4. Outcome measures
Glutamine, HSPs and cytokines were measured from blood taken at the same 
time as the baseline, 2nd and 3rd muscle biopsy.
Glutamine and HSP were measured from muscle tissue taken at baseline, 2nd 
and 3rd biopsy. The patients were followed up until they left critical car e.
2.1.4. Ethical approval
The Research Ethics Committee gave ethical approval for the research study, 
reference number: REC 06/Q1502/43.
The European Drug Regulation Authorities Clinical Trial gave approval, 
reference number: EudraCT: 2006-000576-33 [including the Medicines and 
Healthcare products regulatory agency (MHRA)].
2.2. Preparation of samples
2.2.1. Preparation of plasma for glutathione assays
Arterial blood was collected into Na EDTA tubes (S-Monovette, Nuembrecht, 
Germany) and centrifuged (5min at 1500g). The supernatant was stored at - 
80°C. lOOpl of supernatant was deproteinised by adding 100 pi 1% of 
sulphosalicylic acid (SSA) to the plasma and centrifuged at 20,000g for lOmin 
at 4°C (Eppendorf centrifuge 5417R, Hamburg, Germany). The supernatant 
was used to measure total glutathione content (section 2.3.1) and oxidised 
glutathione content (2.3.2). The protein-precipitated pellets were used to 
measure protein thiol content (2.3.3). It was further used to determine the 
protein content using the Lowry assay (2.3.4).
2.2.2. Preparation of human muscle for glutathione assays
1% sulphosalicylic acid (SSA) was added to muscle powder and homogenised 
(TRI-R Instruments, Model K43, Rockville Centre, N.Y.). The mixture was 
centrifuged at 20,000g for lOmin at 4°C (Eppendorf centrifuge 5417R,
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Hamburg, Germany). The supernatant was used to measure total glutathione 
content (section 2.3.1) and oxidised glutathione content (section 2.3.2). The 
protein-precipitated pellets were used to measure protein thiol content (section 
2.3.3). The protein-precipitated pellets were further used to determine the 
protein content using the Lowry assay (section 2.3.4)
2.2.3. Preparation of samples for SDS-page and western blotting
Reagents
" 0.5 ml Protease inhibitors
o ImM lodoacetimide (50mg) 
o ImM Benzithonium chloride (112,5mg) 
o 5.7mM Phenylmethylsulphonyl fluoride (PMSF) 
(250mg) mixed in 25ml of 1% SDS
■ 9.5mg EGTA
■ 4.5ml 1% SDS
2.2.3.1. Preparation of samples of C2C12 myotubes
C2C12 myotubes (section 2.1.1) were sonicated on ice in the above protease 
inhibitor solution (section 2.2.3) to avoid protein breakdown prior to analysis 
and centrifuged at 20,000g for 10 minutes.
2.2.3.2. Preparation of muscle samples
Vastm lateralis muscle was ground in a pestle and mortar under liquid 
nitrogen. Muscle was homogenized in a 1% solution of sodium dodecyl 
sulphate (SDS) containing protease inhibitors (section 2.2.3), and centrifuged 
at 20,000g for 10 minutes.
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2.3. Analysis of glutathione and protein thiols
2.3.1. Analysis of total glutathione
Total glutathione was measured using the assay developed by Anderson 
(1985) which is based on the reaction of glutathione with 5J5,-dithiobiS"(2- 
nitrobenzoic acid) (DTNB).
Reagents
■ 1% (w/v) sulphosalicylic acid (SSA)
■ Glutathione reductase (600U/ml; Roche Diagnostics Ltd, East 
Sussex, U.K.)
■ Glutathione (oxidized form, Sigma-Aldrich, Dorset, U.K.)
■ Glutathione (reduced form, Sigma-Aldrich, Dorset, U.K.)
■ Stock buffer: 143mM sodium phosphate (Na2HP04), pH 7.5
■ 6.3mM Tetrasodium EDTA (Na4EDTA)
■ Daily buffer: 0.3mM NADPH (Sigma-Aldrich, Dorset, U.K.) 
in 14ml stock buffer
■ DTNB solution: 6mM 5,5,-dithiobis-(2-niti*obenzoic acid) in 
5ml stock buffer
Protocol
Total glutathione content was analysed from supernatant of samples 
homogenised in 1% (w/v) SSA as described above. A solution containing 
16mg of oxidised glutathione and 16mg of reduced glutathione in 10ml of 1% 
SSA was used to prepare a range of standards between 0.081 and 10.4pM. 
1% SSA was used as a blank. A mixture of 75pi of glutathione reductase, 
5.25ml daily buffer, 750pl DTNB and 750f.il distilled water was prepared. 
20pl of standard, sample or blank was placed in a microplate, 200pl of 
mixture was added. The solution was mixed and the absorbance was measured 
at 415nm for lOmins in a microplate reader (Powerwave X340, Bio-tech 
instruments Inc, Vermont, USA.) at a preheated temperature of 37°C.
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2.3.2. Analysis of oxidised glutathione
Oxidised glutathione content was determined by selective derivatising of 
existing reduced GSH by 2-vinyl-pyridine and therefore blocking GSH from 
being quantified. It further does not interfere with glutathione reductase. 
Reagents
■ 2-vinyl-pyridine
■ Triethanolamine (TEA) 50% in dH20
■ pH paper
Protocol
Samples were prepared as for total glutathione analysis. Ipl of 2-vinyl- 
pyridine was added and the sample was vortexed for 1 minute. TEA was 
added (approximately 1.65pl for standards and 1.45pi for samples) and 
vortexed for 1 minute. PH was determined (target pH 6-7) and incubated at 
room temperature for 1 hour. Oxidised glutathione content was determined by 
the protocol for total glutathione analysis (section 2.3.1).
2.3.3. Analysis of protein sulphydryl group (protein thiol)
The sulphydryl content of muscle protein was detennined using the assay by 
Di Monte etal. 1984)
Reagents
■ 0.5M Tris/HCl buffer, pH 7,6
■ 1. ImM DTNB in Tris/HCl buffer, pH 7.6
■ 1% (w/v) SSA
■ 5mM Glutathione (reduced form) in Tris/HCl buffer, (Sigma- 
Aldrich, Dorset, U.K.)
Protocol
The protein precipitate pellets from muscles homogenised in 1% (w/v) SSA 
were resuspended in 200pl of Tris/HCl buffer. These were then further diluted 
1 in 20 with Tris/HCl buffer. Protein content was determined using the Lowry 
assay (section 2.3.4). These dilutions were then used for the sulphydryl group 
assay. A range of standards between 50 and 0.4 pM were prepared from a
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5mM solution of reduced glutathione in Tris/HCl buffer, pH 7.6 (Section 
2.3.1.). Twenty microlitres of DTNB was added to 200jil of samples and 
standards, 200pi of Tris/HCl buffer was used as a blank. These were 
incubated at room temperature for 20mins and then centrifuged (Eppendorf 
centrifuge 5417R, Germany) at 20,000g for Imin. Samples and standards 
were pipetted onto a 96 well microplate. The absorbance was measured at 
415nm using a microplate reader (Powerwave X340, Bio-tech instalments 
Inc, Vermont, USA.). The sulphydryl group content of samples was calculated 
using the standard curve.
2,3,4, Lowry assay for determination of protein content
The method by Lowry et al (1951) was used to determine the protein content 
of samples for protein thiol detennination.
Reagents
■ 1MKOH
* Bovine serum albumin (BSA) Img/ml (Sigma-Aldrich, Dorset, 
U.K.)
- Solution A: 2% Na2C03 in 0.1M NaOH
■ Solution B: 20mM CUSO4.5H2O in 1% trisodium citrate
* Solution C: 500pl of Solution B in 25ml of Solution A
■ Folin and Ciocalteu’s phenol reagent (diluted 1: 1 with distilled 
water, Sigma-Aldrich, Dorset, U.K.)
Protocol
Samples were diluted 1 in 3 with 1M KOH and incubated at 37°C for 3hrs. A 
solution of 1 mg/ml of bovine serum albumin (BSA) was used to prepare a 
range of protein standards from 0-250pg/ml. Solution C was prepared 
immediately before use. Standards and 50pl samples are added to 500 pi of 
Solution C and then incubated at room temperature for lOmins. 50pl of 
diluted Folin reagent was added to samples and standards. The mixtures were 
then vortexed and incubated at room temperature for 30mins. Samples were 
centrifuged at 20,000g (Eppendorf centrifuge 5417R, Gennany) for 1 min and 
200pl of samples and standards were added to a microplate. The absorbance
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of samples and standards was measured at 750nm using a microplate reader 
(Powerwave X340, Bio-tech instruments Inc. Vermont, USA). The protein 
content of the samples was determined using the standard curve.
2.4. Analysis of HSP content by SDS-page and western blotting
2.4.1. Determination of protein content of samples using
Bicinchoninic acid (BCA) assay.
The BCA method was used to analyse the protein content of samples. This 
method is based on the method described by Smith et al. (1985)using a 
commercially available BCA protein assay kit (Sigma Aldrich, Dorset, U.K.). 
Reagents
■ Bovine serum albumin (BSA) hng/ml (Sigma-Aldrich, Dorset, 
U.K.
■ Reagent A: Bicinchoninic acid (BCA) solution, containing: 
25mM BCA-Na, 160mM NaC03.H20, 7.0mM Na2 tartrate, 
O.lmM NaOH and 0.95% NaHCOs, pH 11.2 (Sigma-Aldrich, 
Dorset, U.K.)
■ Reagent B: 160mM CuS04.5H20 (Sigma-Aldrich, Dorset, 
U.K.)
■ Reagent C: 25ml of Reagent A and 500pl of Reagent B
Protocol
A range of standards from 25-250gg/ml were prepared from a stock solution 
of 1 mg/ml bovine serum albumin (BSA). 20pi of sample or standard were 
pipetted in a 96 well microplate. dH20 was used as blank. Two hundred 
microlitres of Reagent C was added to the samples, standards and blank, the 
microplate was incubated a 50°C for 30mins. A stock solution of 1 mg/ml of 
bovine senun albumin (BSA) was used to prepare standards at concentrations 
of between 25-250pg/ml. The absorbance of samples and standards was 
measured at 570mn using a microplate reader (Powerwave X340, Bio-tech 
instruments hie, Vermont, USA).The protein content of the samples was 
calculated using the standard curve.
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2.4.2. Preparation of samples for SDS-PAGE and western
blotting
Reagents
■ Laemmli buffer: 46.03 mg/ml SDS, 20.9% glycerol, 2.1% (v/v) 
P-mercaptoethanol, 0,052 mg/ml bromophenol blue in 0.128M 
Tris/HCl buffer, pH 6.8.
Protocol
After the determination of the protein content of the individual samples using 
the BCA method, lOOpg of total protein was added to an equal volume of 
Laemmli buffer. The positive control was prepared from 0.25pg HSP 70 
(Stressgen Inc, Canada), 0,5pg HSC 70 (Stressgen Inc, Canada), 0.25pg HSP 
60 (Stressgen Inc, Canada) and 0.05pg HSP 25 (Stressgen Inc, Canada) and 
an equal volume of Laemmli buffer. Samples and positive control were loaded 
onto a polyacrylamide gradient gel alongside a molecular weight rainbow 
marker (Amersham Biosciences, U.K.), after 5 min of boiling and subsequent 
passive cooling to room temperature.
2.4.3. Preparation of polyacrylamide gradient gels
Reagents
■ Stock acrylamide solution: 30% acrylamide, 0.8%
bisacrylamide cross-link, in (Protogel, National
Diagnostics, USA)
■ Gel buffer: 1.5M Tris/HCl, 0.384% SDS, pH 8.8. (Protogel 
buffer, National Diagnostics, USA)
■ Stacking buffer: 0.5M Tris/HCl, 0.4% SDS, pH 6.8. (Protogel 
stacking buffer. National Diagnostics, USA)
■ 12% acrylamide solution (100ml): 40ml stock acrylamide 
solution, 26ml gel buffer, 32.9ml dH20
■ 4% stacking gel solution (100ml): 13ml stock acrylamide 
solution, 25ml stacking buffer, 61ml dH20
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■ 10% (w/v) Ammonium persulphate (APS)
* NNN’N’-tetramethylethylene-diamine (TEMED)
Protocol
lOOpl of 10% APS, 10ml of 12% acrylamide solution (see above) and lOpl of 
TEMED were mixed and poured into a glass cavity of 8cm x 10cm x 2mm 
made up by two glass plates and a spacer. The mixture was allowed to 
polymerize. The stacking gel was prepared as follows. lOOpl of 10% APS was 
mixes with 10ml of 4% acrylamide solution (see above). 25pi TEMED was 
added. A well comb was positioned to facilitate well formation. The stacking 
gel was then poured on top of the 12% gel to create a stacking gel of about 1 - 
1.5 cm thickness.
2.4.4. Electrophoresis of proteins
Reagents
■ Electrophoresis buffer: 10X Tris/Glycine/SDS (0.025M Tris, 
0.192M glycine, 0.1% (w/v) SDS; National Diagnostics, USA)
Protocol
Anachem Electrophoresis tank with 10X electrophoresis buffer was used for 
electrophoresis of samples. A constant current of 20mA per gel was applied 
until samples had run through the 4% stacking gel. The current was increased 
to 40mA per gel until the rainbow marker had reached the bottom of the gel. 
The tank was cooled with H20 during electrophoresis.
2.4.5. Western blotting of separated proteins
Reagents
■ Anode 1 buffer: 0.3M Tris in a 20% methanol solution, pH 
10.4.
* Anode 2 buffer: 25mM Tris in a 20% methanol solution, pH 
10.4.
■ Cathode buffer: 40mM 6-amino n hexanoic acid in a 20% 
methanol solution, pH 7.6.
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Protocol
To transfer proteins to a nitrocellulose membrane the Multiphor II 
discontinuous blotting system (Pharmacia, Milton Keynes, U.K.) was 
employed. This system comprised of two graphite plate electrodes. The 12 % 
acrylamide gel was, after removal of the stacking gel, placed on top of a 
nitrocellulose membrane and sandwiched between the electrodes with 
Whatman No 1 filter paper pre-soaked in anode and cathode buffers as shown 
below (Figure 2.3). A constant current of 0.8mA/cm2 was applied to the 
system for 1.5hrs.
Cathode
9 filter papers soaked in Cathode buffer
■ -i
Cel
Nitrocellulose soaked In Anode 2 buffer
6 filter papers soaked in Anode 1 buffer
- "i
3 filter papers soaked In Anode 2 buffer
------------- i
Anode
Figure 2.3 Schematic diagram of western blotting
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2.4.6. Probing of nitrocellulose membrane for HSP content
Reagents
■ PBS solution: 0.05M KH2PO4, 0.05M Na2HP04, 1.3M NaCl 
in dH20, pH 7.2.
■ PBS solution: 0.05M KH2P04, 0.05M Na2HP04, 1.3M NaCl 
in dH20, pH 6.0.
■ PBS/Tween solution: 0.05% (v/v) polyoxyethylene-sorbitan 
monolaurate (Tween 20) in PBS solution.
■ Blocking solution: 5% (w/v) powdered milk in PBS/Tween
Protocol
After transfening the proteins onto the nitrocellulose membrane, the 
nitrocellulose membrane was placed in 50ml of a blocking solution for either 
1 hour at room temperature or overnight at 4°C. The membrane was then 
washed in PBS/Tween solution and analysed for HSP 60, HSC 70, HSP 70 
and HSP 25 using a range of monoclonal or polyclonal antibodies. The 
nitrocellulose membrane was exposed for an hour in 10ml of a solution of 
PBS/Tween containing the primary antibody at the concentration outlined 
(section 2.4.7.) on a rocking table. Following exposure to the primary 
antibody, the membrane was washed 3 x 10 min in PBS/Tween solution. The 
nitrocellulose membrane was then exposed for 1 hour at room temperature to 
the relevant peroxidase labelled secondary antibody in PBS/Tween. 25% Fetal 
calf serum (FCS) was used as a non-specific blocking agent. The membrane 
was then washed as before (SxlOmins in PBS/Tween) and placed in PBS 
pH6,0 for 15min (optimal pH for the peroxidase activity). The membrane was 
developed using SuperSignal West Dura chemiluminescent detection kit 
(Pierce, Rockford, USA). The membrane was placed between acetate sheets 
and analysed using a Bio-Rad Chemi-XRS System and QuantityOne software 
(Bio-Rad, Hercules, USA).
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2.4,7. Primary Antibodies used
HSP 70 (Stressgen Inc, Canada, SPA-810). Mouse monoclonal antibody 
specific against the inducible HSP 70 (HSP 72). A 1:1000 dilution was used.
HSC 70 (Stressgen Inc, Canada, SPA-815). Rat monoclonal antibody specific 
against the constitutively expressed HSC 70 (HSP 73). A 1:1000 dilution was 
used.
HSP 60 (Sigma-Aldrich, U.K, 383-491.). Mouse monoclonal antibody 
against the human HSP 60 amino acids. A 1:500 dilution was used.
HSP 25 (Stressgen Inc, Canada, SPA-801). Rabbit polyclonal antibody 
against the phosphorylated and non-phosphorylated forms of HSP 25. A 
1:2500 dilution was used.
HSP 10 (Stressgen Inc, Canada, SPA-110). Rabbit antibody to the sequence 
near the C-tenninus of HSP 10. A dilution of 1:2000 was used.
2.4.8. Secondary Antibodies
Anti-Mouse (Sigma, Dorset, U.K. Catalogue number A-2554)
Peroxidase conjugated goat anti-mouse IgG (FC specific). A 1:1000 dilution 
was used.
Anti-Rat (Sigma, Dorset, U.K. Catalogue number A-5795).
Peroxidase conjugated rabbit anti-rat IgG. A 1:1000 dilution was used.
Anti-Rabbit (Sigma, Dorset, U.K. Catalogue number A-0545).
Peroxidase conjugated goat anti-rabbit IgG. A 1:1000 dilution was used.
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2.4.9. Removing antibodies and re-probing the nitrocellulose
membrane
Reagents
■ lOOmM p-mercaptoethanol (Sigma-Aldrich, Dorset, U.K.)
■ 2% (w/v) SDS
■ 62.5mM Tris/HCl, pH 6.7
■ PBS/Tween solution, pH 7.2
■ Blocking solution containing 5% (w/v) powdered milk 
PBS/Tween
Protocol
After exposure to chemiluminescent detection solution (Pierce, Rockford, 
USA), the membrane was washed in PBS/Tween solution for 5mins. To 
remove previously used antibodies, the nitrocellulose membrane was 
incubated for 30mins at 50°C in a solution containing the following 
ingredience: lOOmM p-mercaptoethanol, 2% SDS, 62.5mM Tris/HCl, pH 
6.7, The membrane was then washed for 2xl0mins in PBS/Tween solution at 
room temperature and then placed in 50ml of blocking solution for Ihr at 
room temperature or alternatively at 4°C overnight to be ready to be analysed 
for further HSPs.
2.5. Enzyme Linked Immuno Sorbent Assay (ELISA)
2.5.1. Enzyme Linked Immuno Sorbent Assay (ELISA) to
determine cytokine concentrations in serum.
Commercially available solid phase sandwich ELISA kits to detennine the 
concentrations of Tumour Necrosis Factor a (TNF-a) in serum (Human TNF- 
<x, Invitrogen, CA - KHC3011), Interleukin Ibeta (IL lb) in serum (Human 
ILlb, Invitrogen, CA -KHC 0011) Interleukin 6 (IL 6) in serum (Hmnan IL 6, 
Invitrogen, CA - KHC0061) and Interleukin 10 (IL 10) in serum (Human 
IL10, Invitrogen, CA - KHC0101) were used. ELIS As were carried out as per 
manufacturers’ instructions.
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Reagents
■ Used as per manufacturers recommendation. Included in 
commercially available ELISA kits
Protocol - principle of method (manufacturer’s infonnation)
The used ELISA kits were solid phase sandwich ELISA kits, A monoclonal 
antibody specific for the particular cytokine in question was coated onto the 
micro plate wells. All samples were pipetted into the wells including 
standards. The antigen bound to the antibody were pre-fixed onto the 
microplate well. After washing, a second biotinylated antibody against the 
same cytokine was added to bind to the same antibody complex. After 
washing and removal of excess 2nd antibody Streptavidin-Peroxidase 
(enzyme) was added. This bound to the biotinylated 2nd antibody. After 
further incubation and washing a substrate solution was added. This solution 
produces colour when in contact with Streptavidin-Peroxidase. The intensity 
of the colour is proportional to the concentration of the particular cytokine.
The absorbance of samples and standards was measured at 450nm using a 
microplate reader (Powerwave X340, Bio-tech instruments Inc, Vermont, 
USA.).The protein content of the samples was calculated using the standard 
curve.
2.5,2. Enzyme Linked Immuno Sorbent Assay (ELISA) to
determine Cytokine concentrations in cell culture medium
Solid phase sandwich ELISA kits were used to determine the concentrations 
of TNF-a, IL lb and IL 6 in cell culture medium (Mouse TNF-a, Invitrogen, 
CA — KMC3011), (Mouse IL lb Invitrogen, CA - KMC0011), (Mouse IL 6 
Invitrogen, CA - KMC0061). ELIS As were carried out as per manufacturers’ 
instructions.
Reagents
■ Used as per manufacturers recommendation. Included in 
commercially available ELISA kits
Protocol
Identical protocol used in section 2.5.1.
56
The absorbance of samples and standards was measured at 450nm using a 
microplate reader (Powerwave X340, Bio-tech instalments Inc, Vermont, 
USA.).The protein content of the samples was calculated using the standard 
curve.
2.5.3. Enzyme Linked Immuno Sorbent Assay (ELISA) to
determine Heat Shock Protein 70 (HSP 70) concentrations 
in serum
Solid phase sandwich ELISA kits were used to determine the concentrations 
of HSP 70 in senim. ELIS As were carried out as per manufacturers’ 
instructions.
Reagents
■ Used as per manufacturers recommendation. Included in 
commercially available ELISA kit
Protocol
Principle of method (manufacturer’s infonnation)
Similar protocol to protocol used in section 2.5.1.
The absorbance of samples and standards was measured at 450nm using a 
microplate reader (Powerwave X340, Bio-tech instruments Inc, Vermont, 
USA).The protein content of the samples was calculated using the standard 
curve.
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2.6. High Performance Liquid Chromatography (HPLC) to 
determine amino acid content of plasma samples
Regents
■ 35% sulfosalicylic acid (SSA)
■ 75mM sodium acetate pH 5,58 containing 2.5% of acetonitrile
■ 70%v/v acetonitrile/water (ultrapure), 32mM sodium acetate pH
6.2
Protocol
A mixture of components is flushed through a chromatography column. 
Separation of the different compounds is achieved by the different affinities of 
the individual compounds to a stationary phase in the column. The smaller 
the affinity a molecule has for the stationary phase, the shorter the time spent 
in a column. These differential rates of migration as the mixture moves over 
adsorptive materials provide separation (Carrier and Bordonaro.1994) 
Samples were treated with 20j.il of 35% sulfosalicylic acid for each 200j.il of 
sample to precipitate the protein. The solution was vortexed and left at room 
temperature for 20 minutes. The samples were then centrifuged, the 
supernatant separated and 10pl was loaded onto the analyser.
Solvent A: 75mM sodiiun acetate pH 5.58 containing 2.5% of acetonitrile 
Solvent B: 70%v/v acetonitrile/water (ultrapure), 32mM sodium acetate pH 
6.2
Column: 2.1x25mm ODS PTC column. Flowrate: 310jil/min;
Column temperature: 31°C
The ABI 420a amino acid analyser at a wavelength of 254nm was used 
(Heidelberg, Germany). The results were analysed with Dionex Chromeleon 
v4.30 software (Camberley, Surrey, U.K.) (Linse KD et al, 1997)
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CHAPTER 3
EFFECT OF MODIFIED EXTRACELLULAR 
GLUTAMINE CONCENTRATION ON HSP 
CONTENT OF MUSCLE CELLS DURING 
DIFFERENTIATION AND FOLLOWING 
STRESS IN CULTURE
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3.1. Introduction
3.1.1. Muscle weakness and muscle wasting in critical illness: the
role of changes in protein turnover on loss of muscle mass 
and function
Muscle weakness and muscle wasting is common feature in critical illness 
(Hasselgren and Fischer. 1998; Latronico and Bolton. 2011). Muscle fibre 
wasting and atrophy is evident within the first few days of admission to 
critical care and progresses rapidly. Muscle necrosis however occurs 
infrequently (Helliwell et al, 1991; Helliwell et al. 1998), Skeletal muscle 
wasting and muscle weakness is associated with a poor outcome from critical 
illness. Furthermore, muscle wasting and muscle weakness can cause chronic 
disability in critical care survivors (Latronico and Bolton. 2011). It is 
therefore important to abrogate muscle wasting and muscle weakness during 
critical illness.
It is believed that the catabolism of muscle during sepsis results from a 
stimulation of proteolysis and an inhibition of protein synthesis (Vary. 1998) 
although this is a controversial research area and more recently it has been 
suggested that muscle wasting in sepsis is due to increased protein 
degradation, were as protein synthesis appears maintained during sepsis 
(Klaude et al. 2012).
Furthermore, increased levels of circulating cytokines such as TNF-a, which 
was found to be increased more than twice the normal level in sepsis (Damas 
et al. 1989), IL Ibeta and IL 6 have been implicated in catabolic skeletal 
muscle protein metabolism, which occurs during sepsis and SIRS. It has been 
suggested that these pro-inflammatory cytokines inhibit anabolic hormones 
and modulate protein synthesis and degradation (Vary. 1998; Lang et al. 
2002). It has been shown that this catabolic effect of TNF-a is orchestrated via 
NF k B activation which is also regulated by endogenous reactive oxygen 
species and this effect can develop within hours of initiation of sepsis (Li et al. 
1998; Li et al. 2003; Li et al. 2000). Chronic activation of NF R B has been 
implicated in disuse atrophy and contractile dysfunction during mechanical 
ventilation (Smuder et al. 2012).
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3.1.2, Protective effect of Heat Shock Proteins
The expression of stress or heat shock proteins (HSPs) is one of the most 
highly conserved mechanisms of cellular protection and may be central to 
protect against the assault from systemic inflammation as seen during critical 
illness. Heat shock proteins (HSPs) are molecular chaperones that are rapidly 
synthesized within the cell following a variety of stresses such as oxidative 
stress, viral infection, hypothermia, heat and TNF alpha (Brooks and 
Faulkner. 1990; Gething and Sambrook. 1992). Under non-stressful 
conditions HSPs play an important role in protein-protein interactions such as 
folding and assisting in the establishment of correct protein conformation and 
prevention of unwanted protein aggregation (Marimoto et al. 1992). 
Specifically, to regulate a given activity within the cell, HSPs modulate the 
equilibrium between an “active” state and an “inactive” state of a given 
polypeptide. This is achieved by the change of a given protein confirmation, 
instead of changes in the amount of certain proteins by balancing synthesis 
(Hinault et al. 2006).
Under conditions of stress, HSPs are required for stabilization of denatured or 
aggregated proteins (Kiang and Tsokos. 1998; Liu and Steinacker. 2001). All 
HSPs act to preserve cellular integrity. Cells stressed by a sub lethal insult that 
induces the expression of HSPs, are rendered more resistant to subsequent 
extreme stress. One of the possible mechanisms underlying stress-tolerance 
involves the concept that the proper folding of proteins in a cell requires an 
intricate set of folding machinery known as molecular chaperones. Thus, 
when induced following cellular stress, HSPs appear to repair 
denatured/injured proteins or promote their degradation following irreparable 
injuiy (Hightower. 1991)
HSP synthesis is significantly increased in cells after exposure to a wide range 
of cellular stresses (Kiang and Tsokos. 1998). In 1962 Ritossa first showed a 
change the appearance of chromosomes after heat shock (Ritossa. 1962) In 
1975 Gerner and Schneider showed that non-lethal heat treatment carried a 
transient protection against subsequent lethal heat stress (Gerner and
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Schneider. 1975). Subsequently HSPs have been identified to be synthesised 
after heat stress (Ashbumer and Bonner. 1979). The protective effect of 
increased HSP content has been demonstrated in a number of systems 
including skeletal muscle whereby prior heat treatment and the resulting 
increased HSP content provided a significant cytoprotective effect against 
ROS mediated damage (Maglara et al. 2003). Other researchers have shown a 
protective effect of heat treatment in different animal sepsis models (caecal 
perforation; Villar et al. 1994 & LPS endotoxaemia; Chu et al. 1997). In these 
experiments heat treatment resulted in a significant increase in HSP content of 
tissue and significant mortality benefit (Villar et al. 1994; Chu et al. 1997)
The protective effect of increased HSP content in the lung was very elegantly 
shown in a severe sepsis model in Sprague-Dawley rats. Sepsis was induced 
by the two puncture caecal ligation technique. At the time of operation an 
adenovirus expressing HSP 70 was administered to the lung via an 
endotracheal tube. The sepsis-induced lung injury was markedly reduced as 
was mortality in these animals (Weiss et ai. 2002). Another study also showed 
an inverse correlation between HSP 70 levels in lung tissue and serum 
cytokines, TNF-a, IL Ip and IL 6 in an animal lung injury model 
(Vreugdenhil et al. 2003)
It is therefore generally accepted that an increase in the cellular content of 
HSPs protects tissue against subsequent exposure to damage. Systemic 
inflammation as seen during critical illness might resemble such damage. An 
adequate HSP response is therefore believed to be critical for cell survival of 
various tissues in this context.
3.1,3. Muscle regeneration, repair and HSPs
Skeletal muscle is able to regenerate and repair following damage. This 
regeneration and repair depends on a reservoir of stem cells known as satelite 
cells which are present in muscle. When muscle cells are damaged satelite 
cells are activated and develop into myoblasts. Theses immature muscle cells 
(myoblasts) proliferate, differentiate and fuse with remaining muscle fibres 
fascilitating repair (Maglara. 1998; Schultz. 1989),
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Figure 3.1 Schematic illustration of muscle cell maturation adapted from 
Komberg. 2013
It is therefore not only important to address strategies to avoid muscle wasting 
and atrophy but enhance muscle regeneration. It has been suggested that HSPs 
are required during cellular remodelling and repair. Indeed high HSP content 
during this remodelling phase has been observed, which is not surprising 
considering that myoblasts undergo significant remodelling to form mature 
myotubes with the increased expression of muscle specific proteins (Maglara 
et al. 2003). As outlined above, muscle wasting and atrophy are common and 
important phenomenon in critical illness (Latronico and Bolton 2011; Vary 
1998). HSP70 content is significantly down-regulated in multiple models of 
skeletal muscle atrophy (Selsby et al. 2007; Stevenson et al. 2003; Lecker et 
al. 2004). Maglara et al (1998) demonstrated that proliferation, fusion and 
maturation of skeletal muscle stem cells or myoblasts were associated with 
enhanced levels of HSPs. It was further shown that increased HSP 
concentrations fascilitate regeneration of muscle after muscle damage 
(McArdle et al. 2004).
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3.1.4. Glutamine and HSPs
Glutamine, traditionally considered a non-essential amino acid, now appears 
to be a conditionally essential nutrient during stress, injury, or illness (Lacey 
and Wilmore. 1990; Wischmeyer. 2005; see detailed discussion in section 
1,3,4). Glutamine supplementation during critical illness has resulted in 
significant beneficial effects (Novak et al. 2002; Griffith et al. 1997; Singleton 
et al. 2005b); however mechanisms by which this protection occurs are poorly 
understood. One mechanism by which glutamine offers protection is thought 
to be through increased expression of HSPs in a range of tissues. Exposure of 
monocytes (Eliasen et al. 2006b) and intestinal epithelial cells (Wischmeyer et 
al. 1997) to physiologically high concentrations of glutamine during heat 
stress resulted in increased HSP expression and enhanced cell survival. In 
contrast, exposure of human leukocytes to glutamine concentrations below 
normal physiological levels attenuated HSP expression (Oehler et al. 2002), 
Moreover, supra-nonnal glutamine administration was shown to significantly 
increase HSP 70 concentration in a rat sepsis model (Maglara 2003), Of note, 
the glutamine dose correlates with tissue HSP 70 content and importantly 
facilitated tissue protection in several organs (Musch et al. 2001), This 
observation generated the hypothesis that glutamine may exert a direct 
pharmacological effect during sepsis when administered in high doses 
(Wischmeyer. 2006b).
Important to note is that patients initially present with low glutamine, i.e. 
deficiencies, particularly in the critically ill (Biolo et al.. 2005) and so the 
studies described below are aimed both at determining the effect of modified 
glutamine concentration on muscle HSP content, but also the effect of 
depletion followed by repletion of glutamine,
3.1.5, Aim of experiments
The hypothesis for this study was that muscle cells treated with low levels of 
extracellular glutamine will demonstrate modified HSP content and will be 
unable to respond to stress by an increased content of HSPs. Repletion of
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glutamine will reverse this inability to respond to hyperthermia or cytokine- 
mediated stress and will result in modified cytokine production.
The aims of this study are therefore:
1. To determine the effect of different concentrations of extracellular 
glutamine on the development, differentiation and maturation of 
C2C12 myotubes compared with cells in media with the standard 
TiormaT glutamine concentration of 2mM.
2. To identify the effect of different concentrations of extracellular 
glutamine on HSP content of untreated C2C12 myotubes or following 
treatment with hyperthermia or TNF-a compared with cells in media 
with the standard glutamine concentration of 2mM.
3. To examine the effect of different concentrations of extracellular 
glutamine on the release of cytokines by C2C12 myotubes following 
exposme to TNF-a compared with cells in media with the standard 
glutamine concentration of 2mM.
3.2 Experimental design
3,2.1 The effect of different concentrations of extracellular
glutamine on myoblast differentiation and intracellular 
HSP content
This experiment investigated whether different glutamine concentrations 
during myoblast differentiation affect the intracellular HSP content of C2C12 
cells which is known to be important during regeneration. C2C12 myoblasts 
were grown in medium as described in Section 2.1.1. When cells reached 80% 
confluence, media was changed to differentiation medium (DMEM with 2mM 
glutamine, 50 LU/ml penicillin, 50pg/ml streptomycin and 2% horse serum) 
to differentiate die cells into myotubes. After 24 hours of incubation the 
glutamine concentration was changed to the following concentrations: 0, 
O.lmM, 0.25mM, 0.5mM, ImM, 2mM, 5mM and lOmM glutamine. Media
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was changed every 48 hours. At day 9, light microscopy photographs were 
taken after which cells were harvested as described in Section 2.1.1 and 
analysed for HSP content as described in Section 2.2.3.1 and 2.4. For 
schematic illustration of the experimental design see Figure 3.2.
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1mM glutamine
10mM glutamine
O.SmM glutamine
2mM glutamine
0.25mMglutamine
5mM glutamine
0.1 mM glutamine
2mM
glutamine
Change of 
media to 
2% HS.
Change of 
glutamine 
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Change of media every 48 hours
Figure 3.2 Schematic illustration of experimental design. Change of 
glutamine concentration occurred after 24 hours of differentiation. All 
other components in the medium were maintained at same concentrations 
during the experiment. (HS: Horse serum).
3.2.2 The effect of different concentrations of extracellular
glutamine on intracellular HSP content after myotube 
formation - the effect of repletion of glutamine after acute 
deficiency.
This experiment addressed the question whether 48hours of relatively high 
(2.5 x normal) glutamine concentration after a period of relative deficiency in
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an unstressed cell results in an increased intracellular HSP content compared 
with normal and relatively deficient (25% of normal) glutamine concentration. 
To facilitate this, C2C12 myoblasts were cultured in medium as described 
(Section 2.1,1). At day 4 of differentiation the glutamine concentration in the 
medium was changed from 2mM to 0.5mM to resemble a modest glutamine 
deficiency (Biolo et al. 2005). The concentration of 0.5mM glutamine, 25% of 
normal, was used to facilitate a low glutamine concentration and therefore 
resemble a relative deficiency as seen in a clinical setting. A similar 
concentration of 25% of the physiological glutamine concentration has been 
used by other researchers in a human leucocyte model (Oehler et al. 2002). 
At day 7 of differentiation the cells were divided into 3 experimental arms of 
different glutamine concentrations; 0.5mM glutamine, 2mM glutamine and 
5mM glutamine. All other components in the medium were maintained at 
same concentrations as described (Section 2.1.1) and were identical in the 
three treatment arms. Cells were harvested at day 9 for all experiments (Figure 
3.3) to be able to compare the different outcomes in the different experiments 
and to exclude differences in outcome due to time of harvesting. The time 
point of harvesting of cells at 48 hours post change of glutamine concentration 
was chosen as it has been reported that HSP concentrations plateau between 
24-48hours post glutamine administration (Wischmeyer et al. 2001). Cells 
were harvested as described and HSP content analysed as described in Section 
2.1.1.
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Figure 3.3 Schematic illustration of experimental design. Change of 
glutamine was as illustrated. All other components in the medium were 
maintained at same concentrations during the experiment. (HS: Horse 
serum).
3.2.3. The effect of different concentrations of extracellular
glutamine on intracellular HSP content of myotubes 
following heat stress.
This experiment addressed the question as to whether cells exposed to 48 
hours of different extracellular glutamine concentrations demonstrate a 
different intracellular HSP content following a stress which is known to result 
in increased HSP synthesis, hyperthermia. The glutamine concentrations used 
in these studies were chosen to reflect concentrations that were within the 
physiological ranges identified in patients with sepsis (<10mM) and that did 
not demonstrate gross changes in cell growth or differentiation (>0.1mM). 
Thus, the effects of concentrations of 0.5mM glutamine, 2mM glutamine and 
5mM glutamine were examined in this study.
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This study addressed two important questions:
1) Does a relative glutamine deficiency attenuate the ability of C2C12 
myotubes to increase the intracellular HSP content after heat stress?
2) Does a relative high glutamine concentration augment HSP production 
by C2C12 myotubes after heat stress?
To investigate this, C2C12 myoblasts were grown in medium as described 
(Section 2.1.1). At day 4 after cells were placed into differentiation medium, 
the glutamine concentration in the medium was changed from 2mM to 0.5mM 
to resemble a modest glutamine deficiency (Section 3.2.2). At day 7, the cells 
were divided into 3 experimental groups of different glutamine 
concentrations; 0.5mM glutamine, 2mM glutamine and 5mM glutamine. The 
cells received heat treatment (42°C for 30mm) on day 8. The cells were 
harvested at day 9 (Section 3.2.1) and HSP content was analysed by 
SDS PAGE and western blotting (Section 2.4). For schematic illustration of 
the experimental design see Figure 3.4.
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Figure 3.4 Schematic illustration of experimental design. Change of 
glutamine concentration and heat treatment occurred as illustrated. All 
other components in the medium were maintained at same 
concentrations. (HS: Horse serum).
3.2.4 The effect of TNF-a treatment on HSP content and
cytokine production of myotubes maintained in 2mM 
glutamine.
Cytokine production is an integral part of the cell and organism response to 
infection and inflammation and TNF-a is a major pro-inflammatory cytokine 
implicated in SIRS seen in critical illness although the effect of modified 
extracellular glutamine concentrations on the TNF-a induced response of 
muscle cells is poorly understood.
Initial experiments established:
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1) The optimal concentration of TNF-a concentration which resulted in 
increased HSP content of C2C12 myotubes grown in normal 
extracellular glutamine concentration.
2) The effect of (1) on cytokine production following TNF-a exposure.
During these experiments, the extracellular glutamine concentration was 
maintained at 2mM. At day 8, TNF-a (ENZO life science, Exeter, UK) was 
added to the medium at 4 different concentrations (see Figure 3.4). At day 9 
light microscopy photographs were taken after which media and cells were 
harvested and HSP content was analysed (Section 2.4.). Cytokine 
concentration in the media was determined using ELISA (Section 2.5.2). For 
schematic illustration of the experimental design see Figure 3.5.
Change of 
media to 
2% HS.
TNF a 
treatment
Harvesting
10nanog/ml TNF a
25nanog/ml TNF a
2mM glutamine
a? • maintained during 
« experiment 50nanog/ml TNF a
100nanog/mlTNF a
Change of media every 48 hours
Figure 3.5 Schematic illustration of experimental design. Glutamine 
concentration of 2mM was maintained throughout the experiment and 
cells were treated with TNF-a as illustrated. AH other components in the 
medium were maintained at same concentrations during the experiment.
71
3.2.5 The effect of glutamine deficiency and repletion on
intracellular HSP content and cytokine release of C2C12 
cells following treatment with TNF-a.
The aim of these experiments were to determine:
1) The effect of prolonged depletion of glutamine following glutamine 
deficiency on the ability of C2C12 myotubes to increase the 
intracellular HSP content after treatment with TNF-a (at a 
concentration known to induce increased HSPs in cells grown at 
normal glutamine concentration).
2) The effect of a relative high glutamine concentration (2.5 times normal 
levels) following depletion on the ability of C2C12 myotubes to 
increase the intracellular HSP content after TNF-a treatment.
3) The effect of prolonged depletion or relative repletion of extracellular 
glutamine on cytokine release by C2C12 cells following treatment 
with TNF-a.
To investigate this, C2C12 myoblasts were grown in medium as described 
(Section 2.1.1) At day 4 of differentiation the glutamine concentration in the 
medium was changed from 2mM to 0.5mM to resemble a modest glutamine 
deficiency (Section 3.2.2). At day 7 of differentiation the cells were divided 
into 3 experimental groups of different glutamine concentrations: 0.5mM 
glutamine, 2mM glutamine and 5mM glutamine. The cells were treated with 
lOng/ml TNF-a on day 8. The cells were harvested at day 9 (Section 3.2.2). 
For schematic illustration of the experimental design see Figure 3.6. Cells 
were harvested as described (Section 2.1.1) HSP content was analysed by 
SDS-PAGE and western blotting (Section 2.4) and cytokine concentrations 
were measured with ELISA technique (Sections 2.5.2).
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Figure 3.6 Schematic illustration of experimental design. Change of 
glutamine and exposure to TNF-a was as illustrated. All other 
components in the medium were maintained at same concentrations 
during the experiment. (HS: Horse serum).
3.2.6. Statistical analysis
Statistical analysis was carried out with Statistical Package for Social 
Sciences (SPSS) software version 15. Statistical differences were determined 
using ANOVA, when a significant p-value was observed; post-hoc analysis 
was performed to identify significance where appropriate. Significance was 
set at the level of < 0.05. Data are presented as mean ± standard error of the 
mean (SEM).
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3.3. Results
3.3.1 The effect of different concentrations of extracellular
glutamine on myoblast differentiation and intracellular 
HSP content
Figure 3.7 shows representative images of the effect of different 
concentrations of glutamine on the proliferation, fusion and maturation of 
C2C12 myoblasts. Glutamine concentrations of 0 - 0.5mM in the medium 
resulted in impaired cell survival and myotube formation upon light 
microscopy examination compared with cells grown in 2mM glutamine. 
Myotube formation was not overtly altered at concentrations of ImM, 5mM 
and lOmM glutamine in medium.
\
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Figure 3.7 The effect of different concentrations of extracellular 
glutamine on myoblast differentiation at 9 days following change to 
differentiation media (lOx). The glutamine concentration was changed 
after 24 hours of differentiation to 0; O.lmM; 0.25mM; 0.5mM; ImM; 
2mM; 5mM and lOmM respectively. All other components in the medium 
were maintained at same concentrations during the experiment (Section 
2.1.1). Media was changed every 48 hours.
Figure 3.8 shows the effect of different concentrations of extracellular 
glutamine during differentiation of C2C12 myoblasts in cell culture on the 
intracellular HSP 70 content of cells. Data demonstrated that the HSP 70 
content of cells grown in 0.5mM glutamine had a significantly higher content 
of HSP70 compared with the HSP70 content of cells grown in 2mM, 5mM 
and lOmM glutamine respectively. Cells grown in ImM glutamine had a 
significantly higher content of HSP70 compared with the HSP70 content of 
cells grown in 5mM and lOmM glutamine.
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Figure 3.8 The effect of different concentrations of extracellular 
glutamine on the intracellular HSP 70 content of C2C12 cells during 
differentiation. Media were changed every 48 hours. Cells were harvested 
at day 9 of differentiation. HSP 70 concentration expressed in arbitrary 
units. Data presented as mean +/- SEM, n=5. +p = < 0.05.
Following this pilot study, the analyses were restricted to cells treated with 
0.1, 1,2 and lOmM glutamine concentration representing relatively low and 
high concentrations that resulted in modified HSP content.
Figure 3.9 shows the effect of different glutamine concentrations during 
differentiation of C2C12 myoblasts in cell culture on the intracellular HSC 70 
content. Cells were grown in differentiation media containing 2mM 
glutamine. The glutamine concentration was changed after 24hours to 0; 
O.lmM; 0.25mM; O.SmM; ImM; 2mM; 5mM or lOmM respectively. All 
other components of the medium were maintained at same concentrations 
during the experiment as outlined (Section 2.1.1). Media was changed every 
48 hours. Cells were harvested at 9 days following seeding in differentiation 
media.
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Data demonstrated that the HSC 70 content of cells grown in lOmM 
glutamine had a significantly higher content of HSC70 compared with the 
HSC 70 content of cells grown in 2mM. Cells grown in ImM glutamine and 
lOmM glutamine had a significantly higher content of HSC70 compared with 
the HSC70 content of cells grown in O.lmM glutamine.
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Figure 3.9 The effect of different concentrations of extracellular 
glutamine on the intracellular HSC 70 content of C2C12 cells during 
differentiation. Media were changed every 48hours. Cells were harvested 
at day 9 of differentiation. HSC 70 content expressed in arbitrary units. 
Data presented as mean +/- SEM, n=4. #p = < 0.05.
Figure 3.10 shows the effect of different glutamine concentrations during 
differentiation of C2C12 myoblasts in cell culture on the intracellular HSP 60 
content. Cells were seeded in differentiation media containing 2mM 
glutamine. The glutamine concentration was changed after 24hours to 0; 
O.lmM; 0.25mM; 0.5mM; ImM; 2mM; 5mM or lOmM respectively. All 
other components of the medium were maintained at same concentrations 
during the experiment as outlined (Section 2.1.1). Media was changed every
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48hours. Cells were harvested at 9 days following seeding in differentiation 
media.
Data demonstrated no significant difference in the HSP 60 content of cells 
grown in 2mM glutamine compared with the HSP 60 content of cells grown in 
relatively low or high concentrations of glutamine respectively.
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Figure 3.10 The effect of different concentrations of extracellular 
glutamine on the intracellular HSP 60 content of C2C12 cells during 
differentiation. Media were changed every 48hours. Cells were harvested 
at day 9 of differentiation. HSP 60 concentration expressed in arbitrary 
units. Data presented as mean +/- SEM, n=4.
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3.3.2 The effect of different concentrations of extracellular 
glutamine on intracellular HSP concentration after 
myotube formation - the effect of repletion of glutamine 
after acute deficiency.
Figure 3.11 shows HSP 70 content of C2C12 myotubes after growth in 
relatively deficient glutamine concentrations and repleted with either 0.5mM, 
2mM or 5mM glutamine. Cells were seeded in differentiation media 
containing 2mM glutamine. At day 4 media was changed to media containing 
0.5mM glutamine. At day 7 media was changed to media containing either 
0.5mM, 2mM or 5mM glutamine and harvested at day 9. Intracellular HSP 70 
content was not significantly different between the three conditions at day 9 of 
the experiment (Figure 3.3.).
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Figure 3.11 HSP 70 content of C2C12 myotubes after growth in relatively 
deficient glutamine concentrations and repleted with either 0.5mM, 2mM 
or 5mM glutamine. Intracellular HSP 70 content is expressed in arbitrary
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units (as a percentage of positive control). Data presented as mean +/- 
SEM, n=5.
Figure 3.12 shows HSC 70 content of C2C12 myotubes after growth in 
relatively deficient glutamine concentrations and repleted with either 0.5mM, 
2mM or 5mM glutamine. Intracellular HSC 70 content was not significantly 
different between the three conditions at day 9 of the experiment (Figure 3.3).
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Figure 3.12 HSC 70 content of C2C12 myotubes after growth in relatively 
deficient glutamine concentrations and repleted with either 0.5mM, 2mM 
or 5mM glutamine. Intracellular HSC 70 content is expressed as a 
percentage of positive control. Data presented as mean +/- SEM, n=5.
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Figure 3.13 shows HSP 60 content of C2C12 myotubes after growth in 
relatively deficient glutamine concentrations and repleted with either 0.5mM, 
2mM or 5mM glutamine. Intracellular HSP 60 content was not significantly 
different between the three conditions at day 9 of the experiment (Figure 3.3).
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Figure 3.13 HSP 60 content of C2C12 myotubes after seeding (72hours) 
and grown for 72 hours in O.SmM glutamine followed by 48 hours in 
either O.SmM, 2mM or SmM glutamine. Intracellular HSC 70 content is 
expressed in arbitrary units. Data presented as mean +/- SEM, n=5.
3.3.3 The effect of different concentrations of extracellular
glutamine on intracellular HSP concentration of myotubes 
following heat stress.
Initial studies established that treatment of myotubes with a period of 
hyperthermia at 42°C for 30 minutes resulted in a significant increase in HSP 
content of cells compared with the HSP content of untreated cells (Figure
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3.14). This treatment regime was then used for all further studies and 
comparisons presented reflect the HSP content of cells maintained in a 
glutamine deficient media or in a replete media and subjected to hyperthermia 
compared with cells maintained in ‘normal’ 2mM glutamine and subjected to 
hyperthermia.
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Figure 3.14 HSP 70 content of C2C12 myotubes after subsequent 
repletion and following heat treatment compared to no heat treatment. 
Intracellular HSP 70 content is expressed in arbitrary units. Data are 
presented as mean +/- SEM, n=5. *p = < 0.05.
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Figure 3.15 shows HSP 70 content of C2C12 myotubes. Cells were grown in 
differentiation media containing 2mM glutamine. At day 4 media was 
changed to media containing 0.5mM glutamine. At day 7 media was changed 
to media containing either 0.5mM, 2mM or 5mM glutamine. Myotubes were 
then heat stressed at day 8 and harvested at day 9 (Figure 3.4). The HSP 70 
content of heat treated cells grown in 5mM glutamine had a significantly 
higher content of HSP 70 compared with the HSP 70 content of heat treated 
cells in 0.5mM glutamine. These data suggest that the hyperthermia-induced 
HSP70 content of cells was considerably reduced in cells which were 
maintained in glutamine deficient media and this was corrected with 
glutamine repletion.
700 n
(A±i
C
3
600 -
CD
L_
±ini—
TO-
500 -
C
o
ro
400 -
■*->c
0)oc
300 -
oa
o
»'«.
200 -
0.
CO
X
100 -
0
#
0.5mM 2mM 5mM
glutamine glutamine glutamine
Figure 3.15 HSP 70 content of C2C12 myotubes after maintenance of 
glutamine depletion or subsequent repletion and following heat 
treatment. Intracellular HSP 70 content is expressed in arbitrary units. 
Data are presented as mean +/- SEM, n=5. *p = < 0.05.
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Figure 3.16 shows HSC 70 content of C2C12 myotubes. Cells were seeded in 
differentiation media containing 2mM glutamine. At day 4 media was 
changed to media containing 0.5mM glutamine. At day 7 media was changed 
to media containing either 0.5mM, 2mM or 5mM glutamine. Myotubes were 
heat stressed at day 8 and harvested at day 9 (Figure 3.4). Data demonstrate 
that the HSC 70 content of heat treated cells in 5mM glutamine had a 
significantly higher content of HSC 70 compared with the HSC 70 content of 
heat treated cells in 0.5mM glutamine and 2mM glutamine. The HSC 70 
content of heat treated cells in 2mM glutamine had a significantly higher 
content of HSC 70 compared with the HSC 70 content of heat treated cells in 
0.5mM glutamine. These data suggest that the hyperthermia-induced HSC 70 
content of cells was considerably reduced in cells which were maintained in 
glutamine deficient media and this was corrected with glutamine repletion.
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Figure 3.16 HSC 70 content of C2C12 myotubes after maintenance of 
glutamine depletion or subsequent repletion and following heat
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treatment. Intracellular HSC 70 content is expressed in arbitrary units. 
Data are presented as mean +/- SEM, n=5. *p = < 0.05.
Figure 3.17 shows the HSP 60 content of C2C12 myotubes in a similar 
manner to Figures 3.15-3.16. Intracellular HSP 60 content was not 
significantly different between the three conditions at day 9 of the experiment.
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Figure 3.17 HSP 60 content of C2C12 myotubes after maintenance of 
glutamine depletion or subsequent repletion and following heat 
treatment. Intracellular HSP 60 content is expressed in arbitrary units. 
Data are presented as mean +/- SEM, n=4.
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3.3.4. The effect of TNF-a treatment on HSP content and
cytokine production of myotubes maintained in 2mM 
glutamine.
Figure 3.18 shows representative images of myotubes grown and maintained 
in media containing 2mM glutamine at 24 hours following treatment with 
different concentrations of TNF-a. After seeding in differentiation media 
glutamine concentration was kept constant at 2mM glutamine. All other 
components in the medium were maintained at same concentrations during the 
experiment (Section 2.1). Media were changed every 48hours. At day 8 media 
was changed to media containing either lOng/ml, 25ng/ml, 50ng/ml or 
lOOng/ml (Figure 3.5). Myotube appearance was not overtly altered at the 
different TNF-a concentrations.
SOna nog ra m/ml lOOnanogram/ml
Figure 3.18 The effect treatment of C2C12 myotubes with different TNF- 
a concentrations on myotube structure (lOx). Glutamine concentration 
was kept constant at 2mM glutamine throughout the experiment.
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3.3.5. The effect of TNF-a treatment on HSP content of myotubes
maintained in 2mM glutamine.
Initial studies established that treatment of myotubes with lOng/ml TNF-a 
resulted in a significant increase in HSP content of cells compared with the 
HSP content of untreated cells (Figure 3.19). This treatment regime was then 
used for all further studies and comparisons presented reflect the HSP content 
of cells maintained in a glutamine deficient media or in a replete media and 
subjected to treatment with TNF-a compared with cells maintained in 
‘normal’ 2mM glutamine and treated with TNF-a.
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Figure 3.19 HSP 70 content of C2C12 myotubes after glutamine depletion 
(0.5mM) and subsequent repletion (2mM) and treatment with TNF-a 
compared with no TNF-a treatment. Intracellular HSP 70 content is 
expressed in arbitrary units. Data are presented as mean +/- SEM, n=5. 
*p = < 0.05.
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Figures 3.20-3.22 show the HSP 70, HSC 70 and HSP 60 content of C2C12 
myotubes at 24hours following treatment with different TNF-a 
concentrations. After seeding in differentiation media glutamine concentration 
was kept constant at 2mM glutamine. Media were changed every 48hours. At 
day 8 media was changed to media containing either lOnanog/ml TNF-a, 
25ng/ml TNF-a, 50ng/ml TNF-a or lOOng/ml TNF-a (see Figure 3.5). All 
other components in the medium were maintained at same concentrations 
during the experiment (Section 2.1.1). Intracellular HSP 70, HSC 70 and HSP 
60 content was not significantly different between the four conditions 
suggesting a similar induction of HSPs following treatment with all 
concentrations of TNF-a.
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Figure 3.20 HSP 70 content of C2C12 myotubes after treatment with 
different concentrations of TNF-a. Glutamine concentration was kept 
constant at 2mM glutamine. Intracellular HSP 70 content is expressed in 
arbitrary units. Data presented as mean +/- SEM, n=5.
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Figure 3.21 HSC 70 content of C2C12 myotubes after treatment with 
different concentrations of TNF-a. Glutamine concentration was kept 
constant at 2mM glutamine. Intracellular HSC 70 content is expressed in 
arbitrary units. Data presented as mean +/- SEM, n=5.
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Figure 3.22 HSP 60 content of C2C12 myotubes after treatment with 
different concentrations of TNF-a. Glutamine concentration was kept 
constant at 2mM glutamine. Intracellular HSP 60 content is expressed in 
arbitrary units. Data presented as mean +/- SEM, n=5.
3.3.6. The effect of TNF-a treatment on cytokine release by
myotubes maintained in 2mM glutamine
Figures 3.23 - 3.25 and Table 3.1 show the concentrations of TNF-a, IL Ibeta 
and IL 6 in media from C2C12 mouse myotubes at 24 hours following 
treatment with different concentrations of TNF-a. Glutamine concentration 
was kept constant at 2mM glutamine. Data demonstrated that the TNF-a 
concentration in media following treatment with 25ng/ml TNF-a was higher 
than treatment with 50nanog/ml TNF-a or lOOnanog/ml TNF-a respectively, p 
= 0.01. No cytokines were detectable in untreated cells and no difference
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was detected in the IL Ibeta and IL 6 concentrations in media following 
treatment with different concentrations of TNF-a.
lOng/ml
TNF a
25g/ml
TNF a
50ng/ml
TNF a
1 OOng/ml
TNF a
TNF 1392 +/- 43 1441 +/- 31 1194 +/- 45 1053 +/- 12
a pg/ml pg/ml pg/ml pg/ml
IL 8.07 +/- 0.66 7.63 +/- 0.77 7.50 +/- 3.64 8.71 +/- 0.61
Ibeta pg/ml pg/ml pg/ml pg/ml
IL 6 79 +/- 12
pg/ml
87 +/- 41
pg/ml
124+/- 54
pg/ml
80 +/- 26
pg/ml
Table 3.1 Concentrations of TNF-a, IL Ibeta and IL 6 at 24 hours 
following treatment with different concentrations of TNF-a. Cytokine 
concentrations presented as mean +/- SEM.
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Figure 3.23 Media TNF-a concentration at 24 hours following treatment 
with different concentrations of TNF-a. Glutamine concentration was 
kept constant at 2mM glutamine. TNF-a concentration presented as 
mean +/- SEM. Data presented as mean +/- SEM, n=3. #p = < 0.05.
10 nanog/ml 25 nanog/ml 50 nanog/ml 100 nanog/ml 
INF a INF a INF a INF a
Figure 3.24 Media ILip concentration at 24 hours following treatment 
with different concentrations of TNF-a. Glutamine concentration was 
kept constant at 2mM glutamine. Data presented as mean +/- SEM, n=3.
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Figure 3.25 Media IL 6 concentration at 24 hours following treatment 
with different concentrations of TNF-a. Glutamine concentration was 
kept constant at 2mM glutamine. Data presented as mean +/- SEM, n=3.
3.3.7. The effect of different concentrations of extracellular
glutamine on intracellular HSP concentration of myotubes 
following treatment with TNF-a.
No significant difference in intracellular HSP concentration was seen 
following treatment with the different concentrations of TNF-a (Section 
3.3.3). Although there were significant differences observed in the cytokine 
release into medium after treatment of cells with lOng/ml and 25ng/ml, 
compared with 50 and lOOng/ml TNF-a, lOnanog/ml TNF-a was felt to be the 
most appropriate concentration in the following experiment as this level is 
physiologically relevant.
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Figure 3.26 shows representative images of the effect of different 
concentrations of glutamine on myoblast structure at 24hours following 
treatment with 1 Ong/ml TNF-a.
Cells were seeded in differentiation media containing 2mM glutamine. At day 
4, media was changed to media containing 0.5mM glutamine. At day 7 media 
was changed to media containing 0.5mM, 2mM or 5mM glutamine to mimic 
maintained depletion or repletion. Myotubes were then treated with 1 Ong/ml 
TNF-a and harvested 24 hours later (Figure 3.6). Myotube appearance was not 
overtly altered between the different glutamine concentrations.
lOnanoa'ml TNFain lOnanog inl TNFain lOnanog/ml TNFain
O.JmM glutamine 2mM glutamine 5mM glutamine
Figure 3.26 The effect of different concentrations of extracellular 
glutamine on myotubes after maintenance of glutamine depletion or 
subsequent repletion and following treatment with TNF-a (lOx).
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3.3.8. The effect of different concentrations of extracellular
glutamine on intracellular HSP concentration of myotube 
following treatment with TNF-a.
Figure 3.27 shows the HSP 70 content of C2C12 myotubes. Cells were seeded 
in differentiation media containing 2mM glutamine. At day 4 media was 
changed to media containing 0.5mM glutamine. At day 7 media was changed 
to media containing 0.5mM, 2mM or 5mM glutamine. Myotubes were 
stressed with lOng/ml TNF-a at day 8 and harvested at day 9 (Figure 3.6). 
Intracellular HSP 70 was not significantly different between the three TNF-a 
treated groups. Data presented as mean +/- SEM, n=4. *p = < 0.05.
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Figure 3.27 HSP 70 content of C2C12 myotubes after maintenance of 
glutamine depletion or subsequent repletion and following treatment with 
TNF-a. Intracellular HSP 70 content is expressed in arbitrary units. Data 
presented as mean +/- SEM, n=4.
Figure 3.28 shows HSC 70 content of C2C12 myotubes. Data demonstrate 
that intracellular HSC 70 content was not significantly different between the 
three TNF-a treated groups.
95
1800
£ 1600 H
1 
3
(0
i—
■E
C3
Co
CD
r
8coo
oN-
o
COI
1400
1200 -
1000 -
800 -
600 -
400 -
200 -
I
0.5mM
glutamine
2mM
glutamine
5mM
glutamine
Figure 3.28 HSC 70 content of C2C12 myotubes after maintenance of 
glutamine depletion or subsequent repletion and following treatment with 
TNF-a. Intracellular HSC 70 content is expressed in arbitrary units. Data 
presented as mean +/- SEM, n=4.
Figure 3.29 shows the HSP 60 content ofC2C12 myotubes. Data demonstrate 
that intracellular HSP 60 content was not significantly different between the 
three TNF-a treated groups.
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Figure 3.29 HSP 60 content of C2C12 myotubes after maintenance of 
glutamine depletion or subsequent repletion and following treatment with 
TNF-a. Intracellular HSP 60 content is expressed in arbitrary units. Data 
presented as mean +/- SEM, n=4.
3.3.9. The effect of different concentrations of extracellular
glutamine on cytokine production by myotubes following 
treatment with TNF-a.
Figures 3.30 - 3.32 show the concentrations of TNF-a, IL p and IL 6 in the 
media of C2C12 mouse myotubes following treatment with TNF-a. Cells 
were seeded in differentiation media containing 2mM glutamine. At day 4 
media was changed to media containing 0.5mM glutamine. At day 7 media 
was changed to media containing 0.5mM, 2mM or 5mM glutamine. Myotubes
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were treated with lOng/ml TNF-a at day 8 and harvested 24 hours later 
(Figure 3.6).
Data demonstrate that the TNF-a concentration of media from myotubes 
treated with lOng/ml TNF-a and repleted with 2mM glutamine had a 
significantly higher TNF-a release compared with media of myotubes 
maintained in 0.5mM or repleted with 5mM glutamine. Data demonstrate IL 
Ibeta and IL 6 concentration of media from myotubes treated with TNF-a was 
not significantly different between the three TNF-a treated groups.
lOnanog/ml 0.5mM 2mM 5mM
TNF a glutamine glutamine glutamine
TNF a 271 +/- 584 +/- 286 +/-
37 56 39
IL Ibeta 9.98 +/- 8.69 +/- 9.22 +/-
0.405 0.40 1.297
IL 6 8.17+/- 15.06 +/- 12.63 +/-
1.69 2.92 1.40
Table 3.2 Media concentrations of TNF-a, IL Ibeta and IL 6 at 24 hours 
following treatment with TNF-a. Concentrations presented as mean 
(pg/ml) +/- SEM.
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Figure 3.30 Media concentration of TNF-a at 24 hours following 
treatment of C2C12 cells maintained depleted or replete with glutamine. 
Data presented as mean +/-SEM, n=4. *p = < 0.05.
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Figure 3.31 Media concentration of IL Ip at 24 hours following treatment 
of C2C12 cells maintained depleted or replete with glutamine. Data 
presented as mean +/-SEM, n=4.
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Figure 3.32 Media concentration of IL 6 at 24 hours following treatment 
of C2C12 cells maintained depleted or replete with glutamine. Data 
presented as mean +/-SEM, n=4. *p = < 0.05.
3.4 Discussion
Myoblasts undergo significant remodelling to form mature myotubes with the 
increased expression of a number of muscle specific proteins and so relatively 
high HSP content of myoblasts during this differentiation and maturation 
phase has previously been observed (Maglara et al. 2003). Glutamine has been 
implicated to play a role in modulating the intracellular levels of HSPs 
although the effects of modified glutamine concentrations on muscle cell 
growth and maturation has not been examined in detail. This study showed 
that low extracellular glutamine concentrations inhibited maturation and, not 
unexpectedly, gross extracellular deficiency resulted in an inability to produce 
HSPs and cell death. In contrast, marginal extracellular glutamine deficiency.
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i.e. extracellular glutamine concentrations of 0.5mM and ImM glutamine, so 
glutamine concentrations a quarter and half of normal glutamine 
concentrations, appeared to induce a higher level of HSPs in muscle cells, 
possibly reflecting that the cells were stressed at levels of relative deficiency. 
Little effect of modified levels of glutamine on HSP60 content was observed. 
HSP60 is primarily localised to the mitochondria and so data suggest that 
modification of glutamine has little effect on mitochondrial numbers or the 
mitochondria specific stress response.
This study also addressed the effect of either (i) 48hours of relatively high 
(2.5 x normal) glutamine concentration or (ii) continued depletion of 
glutamine, after a period of relative deficiency in an unstressed cell resulted in 
modified HSP content compared with nonnal extracellular glutamine 
concentration and the effect of this on the ability to respond to additional 
stress of either hyperthermia using a standard protocol or to treatment with 
TNF-a to mimic sepsis. To facilitate this, C2C12 myoblasts were grown in 
medium containing 2mM glutamine until maturity (day 4 post addition of 
differentiation media) and then the medium was changed from 2mM to 
0.5mM to resemble a modest glutamine deficiency (Biolo et al. 2005). This 
concentration of 0.5mM glutamine, 25% of normal, was used to facilitate a 
low glutamine concentration and therefore resemble a relative deficiency as 
seen in a clinical setting. A similar concentration of 25% of the physiological 
glutamine concentration has been used by other researchers in a human 
leucocyte model (Oehler et al. 2002). Interestingly, little effect of this acute 
depletion and repletion was seen on myotube HSP content.
Numerous environmental and pathological stressors including heat and TNF- 
a are known to increase the intracellular content of HSPs in a range of cell 
types (Morimoto et al. 1992) where the HSPs are accepted to play a major 
important role in cellular protection and repair. Preconditioning i.e. 
facilitating an increased intracellular HSP concentration prior to damaging 
stress has been shown to increase cell protection and in turn cell survival 
(Maglara et al. 2003). This survival benefit has been shown in several animal 
sepsis models (Villar et al. 1994; Chu et al. 1997; Weiss et al. 2002; Wang et 
al. 2007). Glutamine has been implicated to augment cell survival against a
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variety of stressful stimuli and this beneficial effect has been proposed to 
involve increased intracellular HSP 70 concentrations (Wischmeyer et al. 
1997; Musch et al. 1998). Indeed, intravenous glutamine administration 
correlates with an increased content of HSP 70 in several organs of the rat. 
Importantly a dose dependant response of HSP 70 to glutamine dose was 
observed (Wischmeyer et al. 2001), This observation supported the view that 
glutamine has the remarkable ability to work as pharmacological agent 
facilitating higher intracellular HSP contents with higher administrated 
glutamine doses (Wischmeyer. 2006b). Other authors have suggested that the 
observed deficiency of glutamine during critical illness as modelled by a cell 
culture model and an animal sepsis model is responsible for the attenuated 
HSP 70 response (Eliasen et al. 2006a; Oehler et al. 2002; Wang et al. 2007) 
The experiments described in this chapter have addressed the above questions 
in a muscle cell culture model, namely the question whether extracellular 
glutamine concentrations correlate with intracellular HSP concentrations and 
therefore whether glutamine has pharmacological properties or whether 
extracellular glutamine deficiency attenuated the intracellular HSP 
concentration. Thus, substitution of normal glutamine (2mM) in cell culture at 
a stage of myoblast maturity compared with a deficiency (0.5mM) did not 
influence HSP expression in the unstressed cell.
Data demonstrate that cells maintained in normal (2mM) glutamine were able 
to mount a stress response by significantly increasing the intracellular HSP 
following treatment with either heat or TNF-a and this effect was blunted by 
between 25 and 40% in cells which were maintained in a relatively glutamine 
deficient media at 0.5mM glutamine. In contrast, no appreciable difference 
between the intracellular HSP content was seen between cells maintained at 
2mM extracellular glutamine compared with 5mM extracellular glutamine 
with the exception of HSP 70 whereby intracellular HSC 70 content after heat 
stress was significantly greater in myotubes in medium containing 5mM 
glutamine compared with medium containing 2mM glutamine. These results 
support the importance of maintaining normal glutamine concentrations 
dming stress. Thus, no major difference could be observed between cells 
maintained at 2mM glutamine compared with 5mM glutamine, suggesting no
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added benefit of maintaining glutamine levels at more than twice normal 
level.
This study demonstrated a significant increase in TNF-a production and 
release by muscle cells replete with 2mM glutamine compared with cells 
which were either maintained at 0.5mM glutamine or replete with 5mM 
glutamine. It may be counter-intuitive to measure TNF-a release by cells 
treated with TNF-a, but evidence suggests that muscle cells respond to 
increases in extracellular TNF-a such as during sepsis by the increased 
production of a number of pro- and anti-inflammatory cytokines including 
TNF-a. Pilot data from our laboratory (personal communication, data not 
shown) have demonstrated that the TNF-a added to conditioned media is 
degraded within a short time course and the TNF-a measured in the media in 
this experiment reflects chronic release by C2C12 cells. It is not clear 
whether the observed decrease in TNF-a release from cells maintained at 
0.5mM glutamine or repleted with 5mM glutamine is due to a direct effect of 
glutamine on TNF-a expression as suggested by others (Wischmeyer et al. 
2003). However, it is known that an attenuated as well as an overwhelming 
TNF-a response to stress can also be detrimental. Therefore a significant rise 
after exposure of cells replete with 2mM glutamine and treated with lOng/ml 
TNF-a might represent an adequate response compared to the response seen in 
the 0.5mM glutamine and the 5mM glutamine groups.
Thus, in summary, correction of an extracellular glutamine deficiency rather 
than increases to twice normal extracellular glutamine concentrations appear 
to be the major influence on muscle maturation and ability to raise 
intracellular HSP content following heat and TNF-a stress.
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CHAPTER 4
CLINICAL STUDY
4.1 Introduction
4.1.1 Critical care medicine
Patients admitted to intensive care units suffer from a diverse range of 
conditions ranging from those admitted electively following planned major 
surgery to those admitted as emergencies following some surgical catastrophe, 
major trauma, sepsis or respiratory failure. The variation in age range and 
prior health status is extreme and nowadays Critical Care Units are admitting 
increasingly more elderly, frail or malnourished patients with a median age of 
63years (Harrison et al. 2004),
Importantly, critical illness caries a significant mortality risk. Data from 
129,647 admissions to UK critical care units showed a critical care unit 
mortality of 20,3% and a hospital mortality of 30.8%.
4.1.2 Glutamine and critical illness
In critical ilhiess, glutamine has been postulated to become conditionally 
essential as the increased demand cannot be met by synthesis (see Section 
1.3.1; Griffiths. 2004). Indeed reduced glutamine concentrations have been 
observed in serum and tissues during critical ilhiess (Jackson et al. 1999) and 
low plasma glutamine concentrations have been associated with increased 
mortality in critical illness (Oudermans van Straaten et al. 2001; Rodas P et al, 
2012).
Intravenous glutamine administration has been suggested to be beneficial in 
severe critical ilhiess and has therefore been recommended as part of a par­
enteral nutrition regime (Heyland et al. 2009. Due to the publication of further 
parenteral glutamine trials, this advice has recently been challenged (see 
chapter 1.3.1; Kent and Bongers. 2011).
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4.1.3 Effects of glutamine administration on the stress response
The various effects of glutamine administration have been discussed in detail 
in Section 1.3. It is however important to outline the proposed glutamine 
effects that led to the design of the pilot clinical trial described in this chapter 
(Section 2.1.2).
Glutamine appears to regulate protein turnover in myotubes cultures, 
increasing the half-life of long-lived proteins. This has been proposed to be 
related to the glutamine-induced increase in highly inducible HSP70 (Zhou 
and Thompson. 1997). Further, glutamine appears to be a potent enhancer of 
the HSP response (Nissim et al. 1993; Wischmeyer et al. 1997; Musch et al. 
1998). Intravenous glutamine infusions, over a range of doses (0.15-0,75 
g/kg), are able to enhance HSP concentrations in multiple organs of the rat in 
a dose dependant manner (Wischmeyer et al. 2001). This induction occurs as 
early as 1 hour post-administration and persists for up to 72 hours post­
administration. Moreover, intravenous glutamine infusion prior to a septic 
insult was associated with protection against endotoxin-induced septic shock 
in the rat and could markedly decrease end-organ injury and overall mortality 
(Wischmeyer et al. 2001). It could further be shown that glutamine given 
post-septic insult enhanced HSP 70 and 25 expression, protected against acute 
lung injury and reduced end-organ injury and overall mortality (Singleton et 
al. 2005b). Importantly, the survival benefit from glutamine was abrogated if 
a HSP inhibitor was administered. Indeed it has been suggested that glutamine 
deficiency renders the cells incapable of an adequate HSP response (Oehler et 
al. 2002).
Consequently it has been suggested that glutamine substitution influences the 
HSP response in humans and indeed the observed survival benefit of 
glutamine added to parenteral nutrition to meet a developing deficiency in the 
critically ill might reflect this. Moreover it has been demonstrated that 
glutamine substitution correlates with increased HSP 70 response in the 
critically ill and suggests an improved clinical outcome (Ziegler et al. 2005). 
The ability of cells to induce HSPs following stress is reduced in aged humans 
and animals (Heydari et al. 2000). Tissues from aged animals and blood cells 
from elderly humans both show a reduced production of stress proteins
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following stress (Soti and Csermely. 2003; McConnell et al. 2011) Further, 
reduced glutamine concentration is an independent predictor of mortality in 
critical illness (Rodas et al. 2012; Oudermans Van Straaten et al. 2001). 
However, the low concentration glutamine group was significantly older 
(Oudermans van Straaten et al. 2001). A low HSP concentration in severe 
trauma is correlated with increased mortality. But again, the high mortality 
group was significantly older (Pittet et al. 2002). This lack of adaptation in 
HSP content in the aged animals may be related to a more general failure of 
adaptation to stress.
4.1.4. Effect of HSPs on pro-inflammatory cytokine production
Increased HSP expression has been shown to attenuate plasma concentrations 
of the pro-inflammatory cytokines IL-lp and TNF-a, both in vitro and in vivo 
models and this appears to correlate with improved survival from septic 
insults (Chu et al. 1997) and recent (unpublished) data from our laboratory 
provides evidence for muscle as a major source of pro- and anti-inflammatory 
cytokines. In addition to their local intracellular role, HSPs participate in 
cytokine signalling, cytokine gene expression and enhance antigen 
presentation to T lymphocytes (Pockley. 2003; De Maio. 2011; for detailed 
discussion Section 1.4.5).
4.1.5 Early administration of glutamine
Intravenous glutamine is administered as part of parenteral nutrition 
(intravenous nutrition), which is not usually commenced until several days 
after admission to critical care. This is in line with current recommendation 
regarding nutrition during critical illness (Heyland et al. 2009) as parenteral 
nutrition is not recommended as first line treatment unless gastrointestinal 
failure is present rendering the patient incapable to absorb nutrition via the 
gastrointestinal route. The diagnosis of gastrointestinal failure is currently 
established after at least one of the following gastrointestinal problems: food 
intolerance, gastrointestinal haemorrhage or ileus (Reintam et al. 2006).
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However, as outlined above a HSP response after glutamine administration 
could be observed as early as Ihour after administration in a rat sepsis model 
(Wischmeyer et al. 2001). Importantly, an increased tissue HSP content could 
be observed even when glutamine was administered after the septic insult 
(Singleton et al. 2005b) suggesting that glutamine administration may be 
beneficial as early as possible after admission to critical care.
4.1.6 Establishment of the optimal glutamine dose
In health, glutamine is a nonessential amino-acid with a daily whole body 
turnover of about lOOg per day. It has however been widely accepted that 
glutamine is a crucial component of parenteral nutrition in the critically ill 
patient (Heyland et al. 2009; Section 1.3.6). It has been suggested that the 
supplementation dose should be greater than 0.2 g per kg bodyweight per day 
and others suggest at least 0.4g per kg per day (Glutamine supplementation. 
2009). However, even higher glutamine doses of up to 0.86g per kg 
bodyweight/ day have been proposed to be safe (Tjaeder et al. 2004).
This study was designed to answer the question whether one large glutamine 
dose early in critical illness can affect the serum and muscle tissue HSP 
content. Peak HSP tissue contents have been observed between 24-48 hours 
after administration of one large single dose of glutamine (Wischmeyer et al. 
2001). The ideal time point for tissue and blood sampling was therefore 
chosen as 48hours after glutamine administration to identify the maximum 
effect of the intervention. The second time point after glutamine 
administration (96hours) was used as a further control assuming that one large 
dose of glutamine has no considerable effect beyond 72hours post glutamine 
administration.
4.1.7. Aim of study
This clinical study investigated whether administration of one large dose of 
intravenous glutamine (0.5g/kg bodyweight) as early as possible in critical 
illness resulted in modified HSP content in blood and in muscle tissue at
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48hours and 96hours after randomisation and whether this was associated 
with improved survival.
4.2. Methods
4.2.1 Trial design
Standard treatment as determined by the attending intensivist
Ohours 48hours 96hours- 24hours
Recruitment
and
randomisation 
within 24hours 
of admission 
to Critical care
Intravenous 
infusion of Iso­
caloric 
glucose over 
4 hours. N=15
Intravenous 
infusion of 
0.5mg/kg 
bodyweight 
Glutamine over 
4 hours. N=15
30 patients 
(N = 30) 
muscle 
biopsy at 
baseline 
(three 
passes/ right 
quadriceps) 
and blood 
samples
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Figure 4.1: Schematic illustration of clinical trial
4.2.2 Randomisation
Randomisation of patients was controlled for age as approximately half of 
severely ill intensive care patients are over 65 years with upwards of 25% 
over 75 years of age (Harrison et al. 2004).
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4.2.3. Recruitment
Figure 4.2 illustrates the screening and recruitment of patients for the clinical 
trial. Seventy two patients were screened for eligibility. Nine patients were 
excluded as they were likely to die within 48hours, 7 patients had elevated 
liver enzymes at the time of screening, 2 patients were sufYering from 
concurrent malignancy, 2 patients were prioritised to a concurrent study and 2 
patients were on total parenteral nutrition at the time of screening. It was 
impossible to contact the relatives of 13 patients within 24hours of admission 
to gain assent. Assent was not granted in 22 patients. 15 patients were entered 
into the study (Figure 4.2).
72 patients met inclusion criteria and 
were screened for participation
13 patients
Unable to gain assent within 24hoursof 
admission to critical care
9 patients
were excluded as they were likely to die within 48hours
7 patients
were excluded due to elevated liver enzymes
22 patients 
Assent was not granted
2 patients
were excluded due to malignancy
2 patients
were prioritised to a different study
2 patients
were on parenteral nutrition
15 patients were 
entered into the study
Figure 4.2: Illustration of screening and recruitment of clinical trial
Figure 4.3 illustrates the randomisation of patients for the clinical trial and the 
clinical outcome during their critical care stay. Seven patients were 
randomised to receive the isocaloric glucose infusion (placebo), eight patients 
were randomised to receive the intravenous glutamine infusion. Two patients
111
in the placebo group died within 48hours of randomisation, samples of one 
patient could not be used due to infection risk; Three patients in the glutamine 
group were moved to the ward before the end of sampling, one patient died 
within 48hours of randomisation leaving four patients per treatment group 
with a complet set of samples (Figure 4.3).
15 patients recruited and randomised
7 patients in 
the placebo 
group
8 patients in 
the active 
group
• 2 patient died within 
48hours
• 1 patients samples 
could not be used 
due to infection risk
• 3 patient were moved 
to the ward within 
48hours
• 1 patient died within 
48hours
Figure 4.3: Illustration of the randomisation of patients for the clinical 
trial and the clinical outcome during their critical care stay.
4.2.4. Sample collection and analysis.
Baseline blood and muscle samples were obtained and according to 
randomisation and intravenous glutamine or iso-caloric glucose was 
administered. Further samples were taken at 48hours and 96hours from 
randomisation. Blood samples were centrifuged at 1500g for 5min. Serum and
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plasma was stored at -80°C. Muscle samples obtained (-50 mg) were 
immediately frozen in liquid nitrogen and stored at -80°C for later analysis 
(Section 2.1.2.2.2.1; Section 2.1.2.2.2.2).
4.2,5 Statistical analysis
Statistical analysis was carried out with Statistical Package for Social 
Sciences (SPSS) software version 15. Student’s /-tests were carried out to 
analyse differences between two groups. Where multiple comparisons were 
made, data were analysed with ANOVA and accounted for repeated measures 
where necessary. When a significant F-value was observed; post-hoc analysis 
was performed to identify significance where appropriate. Significance was 
set at the level of <0.05. Data are presented as means ± standard error of the 
mean (SEM).
4.3. Results
4.3.1. Demographics
Figure 4.4 illustrates the age in years of the placebo and glutamine treated 
groups respectively. The mean age of the placebo treated group was 61 years 
with a range from 37 - 83years. 37.5% were women. The mean age of the 
glutamine treated group was 66.5years with a range from 46 - 92years. 42.85% 
were women. There was no significant difference between the age and gender 
of the two groups.
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Figure 4.4: Age in years in placebo and glutamine group. Data presented 
as mean in years +/- SEM, n=7.
Figure 4.5 shows the APACHE II score at time of randomisation (Section 
1.1.1). Mean APACHE II score of the placebo treated group was 19.14 +/- 2.37 
(SEM), range [12 - 29]. Mean APACHE II score of the glutamine treated 
group was 15.29 +/- 1.45 (SEM), range [11 - 22]. Data demonstrated no 
significant difference between the APACHE II score of the placebo treated 
group compared with the glutamine treated group.
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Figure 4.5: APACHE II score at time of randomisation in placebo and 
glutamine group. Data presented as mean +/- SEM, n=7.
4.3.2 Primary Outcomes
4.3.2.1 HSP 70 concentration in serum of patients
Figure 4.6 shows the serum HSP 70 content at three predefined time points. 
Data demonstrate no significant difference between the serum HSP 70 content 
of the placebo treated group compared with the glutamine treated group at any 
time point.
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Figure 4.6: Serum highly inducible HSP 70 content of patients treated 
with either placebo or glutamine at baseline, 48hours and 96hours post­
initialisation of study. Data presented as mean +/- SEM; n=4.
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4.3.2.2 Heat shock protein content of muscle of patients
Figure 4.7 shows the muscle HSP 70 content at three predefined time points. 
Data demonstrate no significant difference between the muscle HSP 70 
content in the placebo treated group compared with the glutamine treated 
group.
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Figure 4.7: Muscle HSP 70 content of patients treated with either placebo 
or glutamine at baseline, 48hours and 96hours post- initialisation of 
study. HSP 70 content is expressed as a percentage of positive control. 
Data presented as mean +/- SEM, n=4.
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Figure 4.8 shows the muscle HSC 70 content at three predefined time points. 
Data demonstrated no significant difference between the muscle HSC 70 
content in the placebo treated group compared with the glutamine treated 
group.
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Figure 4.8: Muscle HSC 70 content of patients treated with either placebo 
or glutamine at baseline, 48hours and 96hours post- initialisation of 
study. HSC 70 content is expressed as a percentage of positive control. 
Data presented as mean +/- SEM, n=4.
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Figure 4.9 shows the muscle HSP 60 content at three predefined time points. 
Data demonstrated no significant difference between the muscle HSP 60 
content in the placebo treated group compared with the glutamine treated 
group.
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Figure 4.9: Muscle HSP60 content of patients treated with either placebo 
or glutamine at baseline, 48hours and 96hours post- initialisation of 
study. HSP 60 content is expressed as percentage of positive control. Data 
presented as mean +/- SEM, n=4 (see Figure 4.3).
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Figure 4.10 shows the muscle a B crystallin concentration at three predefined 
time points. Data demonstrated no significant difference between the muscle 
a B crystallin content in the placebo group compared to the glutamine group, 
a B crystallin content expressed in percentage from positive control. Data 
presented as mean +/- SEM, n=4.
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Figure 4.10: Muscle a B crystallin content of patients treated with either 
placebo or glutamine at baseline, 48hours and 96hours post- initialisation 
of study, a B crystallin content expressed in percentage of positive 
control. Data presented as mean +/- SEM, n=4 (see Figure 4.3).
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Figure 4.11 shows the muscle HSP 10 content at three predefined time points. 
Data demonstrate no significant difference between the muscle HSP 10 
content in the placebo treated group compared with the glutamine treated 
group.
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Figure 4.11: Muscle HSP 10 content of patients treated with either 
placebo or glutamine at baseline, 48hours and 96hours post- initialisation 
of study. HSP 10 content is expressed as percentage of positive control. 
Data presented as mean +/- SEM, n=4 (see Figure 4.3).
4.3.2.3 Cytokine content of serum
Figure 4.12 and 4.13 show the serum concentration of TNF-a and IL 6 at three 
predefined time points. Data demonstrated no significant difference between 
the serum TNF-a or IL 6 content of the placebo treated group compared with 
the glutamine treated group although there appears to be a trend towards
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maintenance of TNF-a levels in the glutamine treated group. Data presented 
as mean +/- SEM, n=4.
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Figure 4.12: TNF-a concentration in serum at baseline, 48hours and 
96hors following randomisation into placebo treated or glutamine treated 
group. TNF-a is expressed in pg/ml. Data are presented as mean +/- 
SEM, n=4.
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Figure 4.13: IL 6 concentration in serum at baseline, 48hours and 96hors 
following randomisation into placebo treated or glutamine treated group. 
IL 6 concentration is expressed in pg/ml. Data are presented as mean +/- 
SEM, n=4.
4.3.1.4 Glutamine concentration in plasma
Figure 4.14 and Table 4.1 show the plasma concentration of glutamine at the 
three predefined time points. Data demonstrated no significant difference 
between the plasma glutamine content in the placebo treated group compared 
with the glutamine treated group. Glutamine content is expressed in mmol/1. 
Data presented as mean +/- SEM, n=4.
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Placebo Glutamine
Mean SEM Mean SEM
(mmol/1) (mmol/1) (mmol/1) (mmol/1)
Day 0
n=7
0.567 0.075 0.539 0.0589
Day 2
n=4
0.589 0.066 0.63 0.131
Day 4
n=4
0.536 0.103 0.65 0.134
Table 4.1: Glutamine concentration in plasma at baseline, 48hours and 
96hours following randomisation into the placebo treated or glutamine 
treated group. Glutamine concentration is expressed in mmol/1. Data 
presented as mean +/- SEM, n=4.
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Figure 4.14 Glutamine concentration in plasma at baseline, 48hours and 
96hours following randomisation into placebo treated or glutamine 
treated group. Glutamine concentration is expressed in mmol/1. Data 
presented as mean +/- SEM, n=4. (Blue line represents 0.42 mmol/1. >
124
0.42mmol/l glutamine concentration in plasma is considered normal 
(Oudermans-van Straaten et al. 2001).
4.3.2.S Correlation of plasma glutamine concentration and serum
HSP 70 concentration.
Figure 4.15 shows the correlation between serum HSP 70 concentration and 
plasma glutamine concentration in patients from both treatment groups at 
96hours following randomisation. The x-axis represents the serum HSP 70 
concentration; the y-axis represents the corresponding plasma glutamine 
concentration. Data demonstrate no significant correlation between the plasma 
glutamine content and the serum HSP 70 concentration.
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Figure 4.15 Correlation between plasma glutamine concentration and 
serum HSP 70 concentration at 96hours following randomisation.
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4.3.2.6 Correlation of plasma glutamine concentration and muscle
HSP content.
Figure 4.16 shows the correlation between muscle HSP 70 content and plasma 
glutamine concentration in patients from both treatment groups at 96hours 
following randomisation. Data demonstrate a weak correlation between the 
plasma glutamine concentration and muscle HSP 70 content.
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Figure 4.16 Correlation between plasma glutamine concentration and 
muscle HSP 70 content at 96hours following randomisation. Correlation 
coefficient r=0.601.
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Figure 4.17 shows the correlation of muscle HSC 70 content and plasma 
glutamine concentration in patients from both treatment groups at 96hours 
from randomisation. Data demonstrate a weak correlation between the plasma 
glutamine concentration and muscle HSC 70 content.
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Figure 4.17 Correlation between plasma glutamine concentration and 
muscle HSC 70 content at 96hours following randomisation. Correlation 
coefficient r=0.738.
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Figure 4.18 shows the correlation of muscle HSP 60 content and plasma 
glutamine concentration in patients from both treatment groups at 96hours 
from randomisation. Data demonstrate no correlation between the plasma 
glutamine concentration and muscle HSP 60 content.
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Figure 4.18: Correlation between plasma glutamine concentration and 
muscle HSP 60 content at 96hours following randomisation. Correlation 
coefficient r=0.552.
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Figure 4.19 shows the correlation of muscle a B crystallin content and plasma 
glutamine concentration in patients from both treatment groups at 96hours 
from randomisation. Data demonstrate a significant correlation between the 
plasma glutamine concentration and muscle a B crystallin content.
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Figure 4.19 Correlation between plasma glutamine concentration and 
muscle a B crystallin concentration at 96hours following randomisation. 
Correlation coefficient r=0.839.
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Figure 4.20 shows the correlation of muscle HSP 10 content and plasma 
glutamine concentration in patients from both treatment groups at 96hours 
from randomisation. Data demonstrate a strong correlation between the 
plasma glutamine concentration and muscle HSP 10 content.
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Figure 4.20 Correlation between plasma glutamine concentration and 
muscle HSP 10 content at 96hours following randomisation. Correlation 
coefficient r=0.945.
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4.3.2.7 Glutathione
4.3.2.7.I. Glutathione content of muscle
Figures 4.21 and 4.22 show the muscle content of oxidised and total 
glutathione at three predefined time points. Data demonstrated no significant 
difference between the muscle content of oxidised and total glutathione in the 
placebo treated group compared with the glutamine treated group.
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Figure 4.21 Oxidised glutathione content of muscle at baseline, 48hours 
and 96hours following randomisation into placebo treated or glutamine 
treated group. Data presented as mean +/- SEM, n=4.
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Figure 4.22 Total glutathione content of muscle at baseline, 48hours and 
96hours following randomisation into placebo treated or glutamine 
treated group. Data presented as mean +/- SEM, n=4 (see Figure 4.3).
4.3.2.T.2. Glutathione concentration in plasma
Figures 4.23 and 4.24 show the plasma concentration of oxidised and total 
glutathione at three predefined time points. Data demonstrated no significant 
difference between the plasma content of oxidised and total glutathione in the 
placebo treated group compared with the glutamine treated group.
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Figure 4.23 Oxidised glutathione concentration of plasma at baseline, 
48hours and 96hours following randomisation into placebo treated or 
glutamine treated group. Data presented as mean +/- SEM, n=4.
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Figure 4.24 Total glutathione content of plasma at baseline, 48hours and 
96hours following randomisation into placebo treated or glutamine 
treated group. Data presented as mean +/- SEM, n=4.
4.3.3 Secondary Outcomes
4.3.3.I. Illness Severity scores used at baseline, 48hours and 
96hours.
Figure 4.25 shows the APACHE II score at three predefined time points. 
Mean APACHE II score of the placebo treated group was 19, range [12-29], 
13.67 [3-21] and 15.8 [7-26]. Mean APACHE II score of the glutamine 
treated group was 15.29, range [11-22], 16.29 [2-30] and 10.5 [2-21]. Data 
demonstrated no significant difference between the APACHE II scores of the 
placebo treated group compared with the glutamine treated group.
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Figure 4.25 APACHE II scores at baseline, 48hours and 96hours. Data 
presented as mean +/- SEM, n=4.
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Figure 4.26 shows the Simplified Acute Physiology Score (SAPS) at three 
predefined time points. Mean SAPS score of the placebo was 43, range [26- 
69], 35.2 [15-54] and 39.2 [18-64]. Mean SAPS score of the glutamine group 
was 38.7, range [30-60], 35.4 [18-60] and 27.2 [13-55]. Data demonstrated 
no significant difference between the SAPS scores of the placebo treated 
group compared with the glutamine treated group.
baseline 48hours 96hours
Figure 4.26 Simplified Acute Physiology Score (SAPS) at baseline, 
48hours and 96hours. Data presented as mean +/- SEM, n=4.
Figure 4.27 shows the Sequential Organ Failure Assessment (SOFA) score at 
three predefined time points. Mean SOFA score of the placebo treated group 
was 9, range [6-12], 6.8 [2-10] and 5.2 [3-7]. Mean SAPS score of the 
glutamine treated group was 5.6, range [1-12], 5.9 [0-19] and 2.5 [0-10]. Data 
demonstrated no significant difference between the SOFA scores of the 
placebo treated group compared with the glutamine treated group.
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Figure 4.27 Sequential Organ Failure Assessment (SOFA) score at 
baseline, 48hours and 96hours. Data presented as mean +/- SEM, n=4.
4.3.3.2. Serum inflammatory markers in patients in the placebo 
and glutamine - treated groups over the first 96hours 
following randomisation.
Figure 4.28 shows the maximal body temperature in 24hour periods starting 
from 24hours before randomisation up to 96hours after randomisation. 
Baseline temperature was recorded as the maximum temperature in the 
24hour period. Data demonstrated no significant difference between the 
temperatures of the placebo treated group compared with the glutamine 
treated group.
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Figure 4.28 Body temperature at baseline, 24hours, 48hours, 72hours and 
96hours following randomisation. Temperature expressed in °Celsius. 
Data presented as mean +/- SEM; n=4.
Figure 4.29 shows the white cell (WCC) count in full blood at five predefined 
time points. Data demonstrated no significant difference between the WCC of 
the placebo treated group compared with the glutamine treated group.
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Figure 4.29 White Cell Count at baseline, 24hours, 48hours, 72hours and 
96hours following randomisation. WCC expressed as white cells x 
109/litre. Data presented as mean +/- SEM, n=4.
Figure 4.30 shows the concentration of the C-reactive protein (CRP) in serum 
at three predefined time points. Data demonstrated no significant difference 
between the CRP of the placebo treated group compared with the glutamine 
treated group. The graph further illustrates the initial worsening during critical 
illness followed by recovery of the patients that survived critical illness.
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Figure 4.30 C-reacrive protein at baseline, 48hours and 96hours from 
randomisation. CRP expressed in mg/litre. Data presented as mean +/- 
SEM, n=4.
4.3.3.3 Length of ventilation
Figure 4.31 shows the length of ventilation of patients in hours. Length of 
ventilation was defined as the time from intubation to either extubation or 
death. Data demonstrated no significant difference between the length of 
ventilation of the placebo treated group compared with the glutamine treated 
group.
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Figure 4.31 Length of ventilation. Length of ventilation expressed in 
hours. Data presented as mean +/- SEM, n=7.
4.3.3.4 Length of stay in critical care
Figure 4.32 shows the length of stay in critical care. Length of stay in critical 
care was defined as the time from admission to either discharge or death. Data 
demonstrated no significant difference between the length of stay on critical 
care of the placebo group compared to the glutamine group.
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Figure 4.32 Length of stay on critical care. Length of stay on critical care 
expressed in hours. Data presented as mean +/- SEM, n=7.
4.3.3.5.Critical care mortality
Figure 4.33 shows the critical care survival. Critical care mortality was 
defined as death while on critical care. Data presented as percentage of 
patients alive in individual groups with 4/8 (50%) in the placebo treated group 
and 6/7 (85.7%) in the glutamine treated group.
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Figure 4.33 Critical Care survival. Data presented as percentage of 
patients alive in individual groups.
4.4. Discussion
Glutamine has been implicated to augment cell survival against a variety of 
stressful stimuli. This beneficial effect has been suggested to involve 
increased intracellular and extracellular HSP 70 concentrations (Wischmeyer 
et al. 1997; Musch et al. 1998; Ziegler et al. 2005) and indeed, intravenous 
glutamine administration has been shown to correlate with an increased 
concentration of intracellular and extracellular HSP 70 (Ziegler et al. 2005). 
Moreover a dose dependant response was observed following glutamine 
administration (Wischmeyer et al. 2001). This observation supported the view 
that glutamine has the ability to work as a “pharmacological regulator of HSP 
expression” facilitating higher intracellular HSP concentrations the higher the 
administrated glutamine dose (Wischmeyer et al. 2006).
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The above described clinical study investigated the hypothesis that early, high 
dose intravenous glutamine supplementation will result in an increased HSP 
content of muscle and serum in the critically ill patient.
Despite previous reports of significantly increased HSP 70 content of serum 
and tissues after intravenous glutamine administration (Ziegler et al. 2005; 
Wischmeyer et al. 2001), no statistically significant difference could be 
observed between the two groups in either of the primary outcome measures 
(HSPs in serum and muscle, glutamine concentration in serum) in the above 
study.
Nonetheless, no significant change of HSP concentration after one large dose 
of intravenous glutamine was observed in either serum or muscle tissue. The 
dose of glutamine used in the clinical trial (0.5g/kg bodyweight) was indeed 
not dissimilar to the glutamine dose used in an animal sepsis model were a 
range of doses from Og/kg bodyweight to 0.75g/kg bodyweight were used 
(Wischmeyer et al. 2001). Indeed even doses of 0,15g/kg bodyweight of 
glutamine did cause a significant HSP 72 rise. This observation raised the 
question as to whether the plasma glutamine concentration influences the HSP 
content in serum and muscle. Indeed, there appears to be a correlation 
between plasma glutamine concentration and muscle content of HSC 70, otB 
crystallin and HSP 10,
Several problems were encountered whilst undertaking this study. Firstly, the 
study was designed as a pilot study, as power calculations were not possible. 
It was therefore decided to recruit 30 patients (Lancaster et al. 2004). Clinical 
trials not infrequently encounter problems with recruitment despite the 
identification of sufficient numbers of patients (Prescott et al. 1999) and 
indeed this study could only recruit 15 patients in the given time available 
(June 2006 — July 2007) which had a significant impact on the end result. 
Further, as outlined in Figure 4.3, data was incomplete in 7 patients for 
reasons outlined.
One inclusion criterion was an APACHE II score of > 10 to guarantee the 
recruitment of patients who were significantly ill. The mean APACHE II in 
treatment and placebo group was 15 and 19, which compared with previous 
studies with APACHE II scores of 13 (Ziegler et al. 2005) and 17 (Griffiths et
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al. 1997) respectively in the treatment groups. ’’Need for parenteral nutrition/ 
gastrointestinal failure” was a further inclusion criterion for both trials 
(Griffiths et al. 1997; Ziegler et al. 2005) not used in this clinical trial. The 
inclusion criterion of “need for parenteral nutrition/ gastrointestinal failure”, 
an independent risk factor for critical care mortality (Reintam et al. 2006), 
selects patients who are potentially more ill than patients without 
gastrointestinal failure. Further, critical care patients are a rather 
heterogeneous population (Carson and Shorr. 2003). Pre - selection of 
patients with “need for parenteral nutrition/ gastrointestinal failure” might 
therefore reduce the heterogeneity of the study group (Carson and Shorr. 
2003).
Rat sepsis models using an endotoxaemia sepsis model (Wischmeyer et al. 
2001) and a caecal ligation sepsis model (Singleton et al. 2005) have shown a 
mortality benefit with an increased intracellular HSP 70 content of several 
tissues of the rat after one large intravenous glutamine dose administered after 
the septic insult. However, the glutamine dose was infused within minutes of 
the septic insult rather than ~ 24hours after admission to critical care as in our 
study and again the animal sepsis models did not suffer from critical care 
heterogeneity (Carson and Shorr. 2003),
In a human endotoxaemia model of healthy volunteers, glutamine at a dose of 
0.25g/ kg bodyweight and endotoxin were administered intr avenously. Plasma 
glutamine concentration increased but no change in plasma TNF-a or IL 6 
was observed with intravenous glutamine, neither did the HSP content of 
blood mononuclear cells change (Andreasen et al. 2009)
Surprisingly, the measured plasma glutamine concentrations in our study were 
relatively normal and only three patients had glutamine concentration below 
0.4mmol/l at the time of randomisation whereas glutamine concentrations are 
found to correlate with mortality (Rodas et al. 2012).
The results of the clinical study do not suggest an effect above the correction 
of a deficiency. Further, the glutamine dose used was significantly large, 
however only administered once. Considering the length of stay of an average 
of > 4 days on critical care, the cumulative dose was considerably smaller 
than previous studies used (Ziegler et al.2005).
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The results therefore need to be interpreted with caution. Noteworthy, one 
patient died in the glutamine treated group compared with 4 patients in the 
placebo treated group and, although not statistically significant, the placebo 
group appeared more severely ill (Mean+/- SEM 15.29 +/- 1.45 glutamine/ 
19.14+/-2.37 placebo).
None the less, this study could not find any evidence to support the early use 
of one large single dose of intravenous glutamine.
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CHAPTER 5
GENERAL DISCUSSION
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5.1. Summary of findings of the work presented
5.1.1. The interaction of extracellular glutamine and HSPs
5.1.1.1. Cell culture analyses
• During differentiation, maturation is inhibited in low extracellular 
glutamine concentrations, below 0.5mM glutamine. Extracellular 
glutamine concentrations of 0,5mM and ImM glutamine during 
differentiation correlated with increased intracellular HSP 70 content 
suggesting a stress response. Higher glutamine concentration did not 
affect intracellular HSP 70 content.
• The intracellular HSP content of myotubes at rest was not affected by 
modulation of extracellular glutamine concentrations after a period of 
relative deficiency.
• The intracellular HSP content of C2C12 myotubes grown in 25% of 
normal glutamine (0.5mM) was reduced following a period of heat 
stress compared with C2C12 myotubes grown in media deficient in 
glutamine (0.5mM) and then replete with standard (2mM) extracellular 
glutamine.
• The intracellular HSP content of C2C12 myotubes grown in 25% of 
normal glutamine (0.5mM) medium and subsequently replete with 2.5 
x normal glutamine concentrations (5mM) and treated with TNF-a 
was increased in a similar manner to C2C12 myotubes grown in media 
deficient in glutamine (0.5mM) and then replete with standard (2mM) 
extracellular glutamine and tr eated with TNF-a.
5.1.1.2. During critical illness
• The clinical study did not show a significant change in plasma 
glutamine concentration at any of the time points measured after one 
large intravenous glutamine dose administered early in critical illness.
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• The clinical study did not show a significant change in HSP content of 
either muscle or serum at any of the time points measured after one 
lar ge intravenous glutamine dose administered early in critical illness.
• No significant difference was observed in any of the secondary 
outcome measures after one large intravenous glutamine dose 
administered early in critical illness,
• A striking correlation was observed between plasma glutamine 
concentration and muscle HSP 10 content and a significant correlation 
was observed between plasma glutamine concentration and muscle 
HSC 70 and a B crystallin content respectively.
5,1.2. Summary of interpretation of results
Higher than normal/sufficient (5mM) extracellular glutamine concentrations 
did not appear to influence the muscle intracellular content of the highly 
inducible HSP 70 compared with standard concentrations in a cell culture 
stress model. Similarly, one large dose of intravenous glutamine in critical 
illness did neither influence the content of HSPs in serum nor muscle. This is 
contrary to observations by other authors (Wischmeyer et al. 2001) who 
administered one dose of glutamine intravenously in a rat sepsis model where 
the glutamine amount given intravenously correlated with the HSP 70 content 
of various tissues of the rat and was greater with greater glutamine doses 
given (Wischmeyer et al. 2001). The observation, that glutamine 
administration in rat and mice sepsis models increases the HSP 70 content 
was reproduced recently (Zhao et al. 2012; Mazloomi et al. 2011). These 
effects were observed in glutamine doses of 0.75g/kg bodyweight 
(Wisclnneyer et al. 2001; Mazloomi et al, 2011) and indeed significant peak 
plasma glutamine concentrations of > 2.5 times in the glutamine treatment 
group compared with the control goup was observed (Wischmeyer et al. 
2001).
Of course comparisons between our cell culture model and animal sepsis 
models need to be made with caution. The heat stress and the TNF-ct stress in 
the cell culture model does not necessarily resemble stress during an animal
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sepsis model. Further, although we tried to develop in house HPLC to be able 
to determine intracellular glutamine concentrations, this was not established 
between 2004 and 2007. We can therefore only assume that the extracellular 
glutamine concentrations correlate with the intracellular glutamine 
concentrations.
Maintenance of a moderate deficiency (to 25% of normal values; 0.5mM) of 
glutamine resulted in reduced HSP 70 content of heat stressed muscle cells 
compared with the HSP 70 content of heat stressed cells repleted into standard 
glutamine concentrations. This observation is in concordance with previous 
work showing a reduced HSP 70 content of tissues during glutamine 
deficiency (Oehler et al. 2002). The importance of a glutamine deficiency is 
further highlighted by the possible correlation between the plasma glutamine 
concentration and several muscle HSPs in the clinical trial suggesting the 
importance of the plasma glutamine concentration rather than the glutamine 
amount given at the time of critical illness. The cell culture experiments as 
well as the clinical trial do therefore highlight the effect of a glutamine 
deficiency on HSP content and the importance to conect a clinical deficiency 
to improve tissue protection.
We could not show a beneficial effect of one large single dose of intravenous 
glutamine early during critical illness. Neither could we show a significant 
increase in plasma glutamine concentrations 48hours and 96hours after one 
large dose of intravenous glutamine. In an animal sepsis model (Wischmeyer 
et al. 2001) the peak glutamine concentration was measured after ~15 minutes 
of administration and returned to normal after 4 hours. Importantly glutamine 
was given directly after the septic insult. Of course that was not achieved in 
our clinical trial and cannot realistically be achieved in clinical medicine with 
a delay from insult to presentation of hours to days. Nonetheless, evidence 
exists to suggest that parenteral nutrition with alanine-glutamine dipeptide at a 
dose of 0.5g/kg bodyweight significantly increases the serum HSP 
concentration after 7 days (Ziegler et al. 2005), however not as a single large 
bolus of intravenous glutamine.
The importance of plasma glutamine concentration was highlighted again 
recently in a study of > 170 critical care patients with a significantly increased 
mortality with plasma glutamine concentrations below 400mmol/l (Rodas et
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al. 2012). Furthermore plasma glutamine concentrations above 930mmol/l 
were associated with increased mortality too (Rodas et al. 2012). Therefore, 
determination of the plasma glutamine concentration, correction of a 
deficiency and avoiding plasma glutamine levels above 930mmol/l rather than 
the overall amount of glutamine administered is of paramount importance. 
Routine measurements of plasma glutamine concentration are currently not 
feasible for practical and financial reasons (Kent and Bongers. 2011). 
Currently no pre-selection criteria for an “at risk” group, i.e. a group with a 
low plasma glutamine concentration, exist, although illness severity as well as 
age was suggested to correlate with low plasma glutamine concentrations 
(Oudemans-van Straaten et al. 2001; Novak et al. 2002)
Ample evidence exist that increased intracellular and extracellular HSP 
concentrations are beneficial for survival during sepsis (Le Grand and Alcock. 
2012; Me Connell et al. 2011; Aschkenasy et al. 2011). Strong evidence exist 
that intravenous glutamine administration correlates with intracellular and 
extracellular HSP concentrations ((Zhao et al. 2012; Mazloomi et al. 2011; 
Wischmeyer et al. 2001; Ziegler et al. 2005). It is not yet clear whether this 
effect is afforded by the conection of a deficiency (Oehler et al. 2002) or as a 
direct effect of glutamine administration (Wischmeyer P. 2006b)
5.2. Implementation for future treatments of critical ill patients
The cell culture experiments confirmed the need of a “normal” glutamine 
concentration during stress to generate a significant HSP response. It further 
supported the observation that a relative deficiency attenuated an appropriate 
HSP response. On the other hand, although little beneficial effect was seen at 
supra-maximal supplementation levels, no adverse effect was observed. 
Several recent large scale trials suggest a possible change of recommendation, 
although the trials have been criticised due to the methodology used. The 
results of the largest trial undertaken so far are still awaited. However, several 
fundamental questions remain unanswered and are unlikely to be answered. 
Current evidence suggests that intravenous glutamine administration causes 
no significant side effects (Kent and Bongers. 2011; Rodas et al 2012) 
reported an increased mortality risk with plasma glutamine concentrations
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below 400mmol/l and above 930mmol/l in a prospective observational trial of 
174 critical care patients. No glutamine was administered during this trial. It 
therefore remains unclear whether glutamine concentrations above 
>930mmol/l following intravenous administration increases the mortality risk. 
The current study has suffered due to the low numbers finally recruited, which 
are not sufficient to show any marginal effects but have allowed power 
calculations to be undertaken for larger scale intervention studies . The plasma 
glutamine concentration was not significantly affected after one large 
intravenous glutamine dose suggesting the need for larger or longer 
supplementation levels in future studies although these need to be mindful of 
potentially detrimental effects of supra-maximal doses of glutamine.
5.3 Future studies
Previous data have shown that high dose glutamine administration influences 
the HSP 70 response in critical illness in animal sepsis models and this effect 
was observed in a dose dependent manner (Wischmeyer et al. 2001). Further a 
clinical trial showed increased serum HSP 70 after glutamine administration 
(Ziegler et al. 2005). The cell culture results reported in Chapter 3 do not 
suggest a dose dependant response of HSP 70 in muscle following glutamine 
administration above ‘normalisation’. However the highest glutamine dose 
used was “only” 2.5x the normal extracellular glutamine concentration. Future 
studies may need to explore the question of whether higher extracellular 
glutamine concentrations may influence the ability of cells to respond to 
stress.
hi an animal sepsis model a HSP response could be observed as early as one 
hour after glutamine supplementation (Wischmeyer et al. 2001). The clinical 
study reported here did not observe any effect of glutamine supplementation 
for up to 96 hours after treatment. Although suggested in an animal model, it 
is not clear whether 48 hours is the best time point to investigate an HSP 
response in human. Future studies should therefore explore shorter time 
intervals. The clinical study reported here also did not show a significant 
change in plasma glutamine concentrations after one large intravenous 
glutamine dose. It is therefore likely that any future study will need to address
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the problem of intravenous glutamine administration to significantly increase 
the plasma glutamine concentrations in any future study.
The cell culture experiments and the clinical trial suggest a correlation 
between glutamine concentration and intracellular HSP content, particularly 
the small HSPs. The relevance of this observation is not clear and will need 
further evaluation, potentially using transgenic mice either overexpressing or 
knocked out for these HSPs. Further, long term follow up trials are needed to 
review the role of HSPs during recovery and muscle repair.
Recent trial data of several large scale intravenous glutamine intervention 
trials have been disappointing suggesting no significant effect of parenteral 
glutamine on critical care mortality (Andrews et al. 2011; Wernerman et al. 
2011; Grau et al. 2011). However, neither were the patients stratified for the 
risk of low plasma glutamine concentrations nor were plasma glutamine 
concentrations determined prior to randomisation. Any further glutamine 
studies need to address this knowledge deficit by
1. Identifying patients as risk from low plasma glutamine concentrations
2. Randomising patients to glutamine administration versus control with 
established low glutamine concentrations.
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ABSTRACT RELATED TO WORK
Poster presentation at the 2007 conference of the European Intensive 
Care Society, in Berlin, Germany.
Glutamine influences viability and Heat shock protein content of C2C12 mouse 
myoblasts in culture. (No 1218)
Thomas Bonders. Richard D. Griffiths and Anne McArdle.
ICU Whiston Hospital, Prescot and Division of Metabolic Cellular
Medicine, School of Clinical Science, University of Liverpool, L69 3GA,
United Kingdom.
Studies examining the effect of glutamine supplementation in critical illness 
have demonstrated significant beneficial effects in animals and man although 
the mechanisms by which this protection occurs are not understood. We 
aimed to examine the effect of various glutamine concentrations on the ability 
of C2C12 myoblasts to differentiate and its effect on Heat shock protein 
expression (HSP).
Methods C2C12 myoblasts were raised under standard conditions. 
Differentiation to multinuclear myotubes was induced by replacing PCS with 
2% horse serum. Cells were supplemented with glutamine at concentrations 
between 0 and lOmM throughout and this was replaced every other day. 
Photographs were taken at day 9 of differentiation. HSP content of cells was 
determined using western blotting as described previously (Maglara et al, 
2003). Results At low levels of glutamine (0 - 0.25mM), cell survival was 
greatly impaired and differentiation was reduced. However HSP70 content of 
cells grown in media of 0.5mM and ImM Glutamine showed an increased 
HSP 70 response compared with cells grown and differentiated in 
physiological glutamine concentrations. No effect of higher glutamine 
concentrations (between 2 - lOmM) on cell viability or HSC70 and HSP 70 
content was evident.
Discussion Glutamine supplementation affects Heat Shock Protein (HSP) 
expression in various cell types. Several authors have suggested that exposure 
of cells to relatively high concentrations of glutamine results in increased HSP 
expression and an enhanced cell survival (Wischmeyer et al.1997) Skeletal 
muscle degeneration occurs following a number of insults and muscle repair is 
reliant upon activation and differentiation of stem cells or myoblasts to form 
mature multinucleated muscle. Transgenic studies in our laboratory have 
demonstrated that the ability of skeletal muscle cells to produce HSPs during 
stress and development is crucial to the correct maturation and functioning of 
these cells (McArdle et al, 2004). Our data suggests that the glutamine 
concentration for optimal myoblast proliferation and differentiation is ~2mM. 
Reduction below this value resulted in reduced cell viability and modified 
HSP although levels higher than physiological had little effect on cell growth 
and differentiation. This might suggest that reduced Glutamine concentrations 
itself acts as a stressful stimulus. Further reduction however renders the cell 
unable to respond at all.
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Exogenous glutamine: an update of the clinical evidence 
Kent W, Bongers T.
Southport and Ormskirk District General Hospital, Merseyside, UK
Glutamine has been shown to play an important role in a number of 
biochemical and immune processes. While in health it is considered a non- 
essential amino acid, in patients with critical illness it has been suggested that 
reduced endogenous production can be insufficient to meet increased demand. 
Exogenous glutamine supplementation has been studied extensively for more 
than two decades, including in several recently published large trials, but its 
role still remains controversial. A number of trials and meta-analyses have 
shown significant morbidity and mortality benefits of supplementation that 
have not always been replicated in other studies. There is also evidence for 
various effects on the immune system, antioxidant status, glucose metabolism 
and heat-shock protein response. This review critically appraises the current 
evidence regarding glutamine supplementation and the possible reasons for 
disparity.
Crit Care Med. 2007 Sep; 35(9 Suppl):S545-52.
Exogenous glutamine: the clinical evidence.
Bongers T. Griffiths RD. McArdle A.
Division of Metabolic and Cellular Medicine, School of Clinical Science, 
University of Liverpool, UK.
Abstract
We know that critically ill patients suffering from undernutrition with a 
limited nutritional reserve have a poorer outcome. Furthermore, having a low 
body mass index has been shown to be an independent predictor of excess 
mortality in multiple organ failure. Therefore, nutritional support has gained 
increasing interest in critical illness with the hope of preventing or attenuating 
the effects of malnutrition. A negative nitrogen balance is the characteristic 
metabolic feature in critical illness, with the major protein loss derived from 
skeletal muscle. In particular', glutamine concentrations are rapidly reduced in 
plasma and muscle. Over the last 20 years or so, increasing evidence is 
emerging to support the use of glutamine supplementation in critical illness. 
Clinical trials have found a mortality and morbidity advantage with glutamine 
supplementation. The advantage appears to be greater the more glutamine is 
given and greater again when given parenterally. Various modes of action 
have been postulated. Glutamine seems to have an effect on the immune 
system, antioxidant status, glucose metabolism, and heat shock protein 
response. However, the benefit of exogenous glutamine on morbidity and
17B
mortality is not universally accepted. This review critically appraises the 
current clinical evidence regarding glutamine supplementation in critical 
illness.
Curr Opin Crit Care^ 2006 Apr; 12(2): 131-5.
Are there any real differences between enteral feed formulations used in 
the critically ill?
Bongers T, Griffiths RD.
ICU Whiston Hospital and School of Clinical Science, University of 
Liverpool, Liverpool, UK, tbongers@liverpool.ac.uk
Abstract
PURPOSE OF REVIEW: We know that adequate nutritional support is 
essential in the treatment of critically ill patients, because it can, if applied 
appropriately, improve the clinical outcome. Increasing evidence seems to 
suggest that malnutrition itself is a predictor of poor outcome in intensive 
care, and significant underfeeding during intensive care stay increases the risk 
of bloodstream infections. The purpose of this review is to highlight recent 
advances in enteral nutrition in the critically ill adult patient.
RECENT FINDINGS: Recent studies suggest that tight glycaemic control is 
associated with improved outcome. Enteral feeding should be encouraged, 
using simple feeding protocols, and started early if safe to do so. Gastric 
residual volumes do not correlate with the risk of aspiration, and therefore 
should be used with caution in feeding protocols. Conflicting evidence exists 
for supplementation with antioxidant and immuno-nutrition in the critically 
ill. Glutamine and fish oil/borage oil should be considered for bums patients 
and patients with adult respiratoiy distress syndrome, respectively.
SUMMARY: This review offers information regarding the latest 
developments in nutritional support via the enteral route. Further research is 
needed to clarify the role of enteral supplements such as antioxidants and 
'immune modulating substances'.
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